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ABSTRACT 
 
        There is a strong market demand for enantiomerically pure drugs. One solution to this 
problem is to develop a simple methodology for transferring synthetically designed racemic 
drugs into optically pure ones. Many synthetic drugs are by nature amides, therefore, amino acid 
based models for transformation of racemates into optically pure compounds were selected for 
this study. Formation of self-assembly molecular aggregates of properly modified amino acids 
was observed with and without the presence of cyclodextrins. Cyclodextrin assisted formation of 
polymer-like self-assemblies and enantiomeric resolution of these amino acids were studied 
using 1D and 2D NMR spectroscopy, EleacroSpray Ionization Mass Spectroscopy (ESIMS), 
Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectroscopy (MALDI-TOF-
MS).  The role of π-π stacking interaction between aromatic moieties in enantiomeric resolution 
was demonstrated by calculating association constants of this host-guest system. 
        Dolabellane diterpenoids share the unique feature of a trans-bicyclo[9.3.0]tetradecane and 
most of them express antimicrobial, antitumor and antiviral activities. They are primarily 
obtained from marine resources. Dolabellane diterpenoid B was isolated from the Okinawan soft 
coral of the genus Clavularia by Iguchi and co-workers. Current efforts toward the synthesis of 
dolabellane diterpenoid B is discussed along with the plans for completion of its synthesis.
  1
  
I. Introduction 
 
1.1 Cyclodextrins 
    The cyclodextrins (CDs), also called cycloamyloses and Schrödinger dextrins, are cyclic 
oligosaccharides formed from starch by the action of certain bacteria, such as Bacillus macerans, 
Klebsiella oxytoca, Bacillus circulans.1,2 Three readily available cyclodextrins, α-CD, β-CD and 
γ-CD, are commonly referred to as the natural CDs. They have six, seven and eight D-
glucopyranosyl units, respectively, connected through α−(1→4)-glycosidic bonds.  In 1891 
Villier3 isolated approximately 3.0 g of a crystalline substance from ~1000 g starch and named it 
“cellulosine”.  This substance later proved to be α-cyclodextrin.  Subsequently, Freudenberg and 
co-workers described the first purification scheme for the isolation of homogeneous and pure 
crystalline α-and β-CDs and postulated the cyclic structure of these CDs in 1936.4  In 1948, γ-
CD was discovered, also by the same group.5 Subsequent structural analysis of CDs revealed that 
CDs with five or less glucopyranosyl units are too strained, while on the other hand, CDs with 
more than eight residues (for example δ-CD with nine glucose units) are structurally too flexible 
and therefore, prone to hydrolysis.6  The hydrolysis rate of CDs increases in the order of α-CD 
<β-CD < γ-CD< δ-CD.  
  2
 
 
Figure 1.1   The structures of α, β and γ cyclodextrins6 
 
 The 4C1 chair conformation of the glucose unit makes the cyclodextrin shape appear as a 
conical cylinder or wreath-shaped truncated cone, in which all secondary hydroxyl groups (the 
O(2)-H and O(3)-H)) are on one side of the ring, and the primary hydroxyl groups (O(6)-H) are 
situated on the other side of the ring. The inner surface of the cavity is dominated by C-3 CH 
groups, C-5 CH groups and glycosidic oxygens atoms and are relatively hydrophobic7.  The 
primary hydroxyl rim of the cavity opening has a somewhat reduced diameter compared to the 
secondary hydroxyl rim, since free rotation of primary hydroxyl groups reduce the effective 
diameter of the cavity.2 
 
7.8 Å
α-CD β-CD γ-CD
Hydrophobic cavity
Secondary hydroxyl
groups
Primary hydroxyl 
groups
 
Figure 1.2  Schematic representations of α, β and γ cyclodextrins 
 
α-Cyclodextrin β-Cyclodextrin γ-Cyclodextrin 
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Table 1.1   Characteristics of α, β and γ−CD 
 α− CD β−CD γ−CD 
no. of glucose units 6 7 8 
mol. wt 972 1135 1297 
solubility in water, g 100 mL-1 at room temp. 14.5 1.85 23.2 
cavity diameter, Å 4.7-5.3 6.0-6.5 7.5-8.3 
approximate volume of cavity, Å3 174 262 427 
 
 Some of the most important characteristics of CDs are summarized in Table 1.1. β-CD is 
the least soluble in water compared to α- and γ-CD due to a perfect arrangement of hydrogen 
bonding on the CD ring and a few interactions with surrounding water molecules.  During the 
complex formation with other molecules, cavity size plays a very important role. The cavity size 
of CDs increase in the order of α-CD <β-CD < γ-CD. Surprisingly, CDs with more than eight 
glucose units (bigger than γ-CD) have an even smaller cavity size compared to γ-CD due to the 
fact that their shape is not anymore conical but rather collapsed.2 
 
1.2 Cyclodextrin Inclusion Complexes 
 The inner surface of the CD cavity is slightly hydrophobic because it is occupied by the C-
3 and C-5 hydrogens.  On the other hand, the major interactions in aqueous media between the 
surrounding water molecules and CDs occur through the primary hydroxyl group from the CD 
ring.  In this way a hydrophobic cavity (host) is formed that can bind a substrate (guest) of the 
proper shape and polarity (Figure 1.3) 2. These CD complexes containing the appropriate “guest” 
molecule are usually referred to as an inclusion complex.  
  4
 
CH3
CH3
+
CH3
CH3
 
Figure 1.3   Schematic representation of a CD inclusion complex formation. p-Xylene is the  
guest molecule; the small circles represent water molecules. 
 
 CDs can form inclusion complexes with a wide variety of different guest compounds8 
including phenols,9-11 aliphatic alcohols,12-19 diols,17-19 amino acids,20-21 hydrocarbons,12-22 
aromatic amines,23 amines and acids, 24oligopeptides,25  sugars, 26 azo compounds,27-30 
cyclohexanes,31 naphthalene derivatives and other aromatic compounds, 32-35 as well as different 
pharmaceutical compounds.36-37. During the binding of these guest molecules with native or 
modified cyclodextrins, the hydrophobic part of the guest molecule enters the core of the 
cyclodextrin cavity, while the hydrophilic part, which is often charged, stays on the periphery of 
the primary or secondary rim of the cavity. 38 Literature reports have indicated that the most 
frequent the host:guest ratio observed is 1:1; however 2:1, 1:2, 2:2, or even higher order 
complicated associations also exist.39-54  In fact, a ternary complex consisting of a single guest 
molecule complexed with two different cyclodextrins was recently reported by Giorgi and Tee. 55 
 The stability of these cyclodextrin inclusion complexes can be determined by the 
calculation of the complex stability, or binding constant, Ka.  In aqueous solution equilibrium is 
established between the dissociation and association of complexes, and is governed by the 
  5
thermodynamic equilibrium shown below.  In this equation, (L) is ligand or host cyclodextrin 
and (S) is substrate or guest molecule.6  
S + L SL
SL  +  L
S  +  SL
SL2
S2L  
 
The stepwise binding constant for these equilibriums, denoted K11, K12 and K21, are defined here.  
[SL]
[L][S]
[SL2]
[L][SL]
[S2L]
[SL][S]
=
=
=
K11
K12
K21
 
 The cyclodextrin inclusion complexes studied so far have been performed using the native 
CDs (α-CD, β-CD and γ-CD) and many covalently modified CDs prepared from native forms.56-
61  Larger cyclodextrins having more than eight glucose units are not practical host molecules, 
due to the weaker driving force of the substitution of the high enthalpy water molecules with 
guest molecules in the CD cavity.2 
 
1.3 Spectroscopic Methods used for Studying CD Inclusion Complexes 
 There are a number of interactions responsible for the formation of inclusion complexes 
between CDs and the guest molecule.  These interactions include hydrogen bonding,62,63 Van der 
Waals’ forces,64,65 and π−π interactions.66,67 There are a number of different methods employed 
by researchers studying the formation of inclusion complexes.68  Among them are electron-spin 
resonance (ESR) spectroscopy,69,70 proton nuclear magnetic resonance (NMR) spectroscopy,71-73 
  6
ultraviolet (UV) and visible spectroscopy,74-76 circular dichroism (CD) spectroscopy or optical 
rotatory dispersion (ORD),77-80 Raman spectroscopy,81 fluorescence spectroscopy,82,83 X-ray 
analysis,84-87 potentiometry,88 positron annihilation,89 and thermoanalytical methods,90 electro-
spray ionization mass spectroscopy (ESIMS).91-101  
 
1.3.1 NMR Spectroscopy for the Study of CD Inclusion Complexes 
 The first report of CD inclusion complexes studied used 1H NMR spectroscopy, was 
performed in an aqueous media, and appeared in the literature thirty years ago.98-100 However, 
from that point forward,101-103 new 2D NMR methods and high-field instruments have 
completely changed the way research has been applied to the study of the formation of 
cyclodextrin complexes. 104  For instance, during the complex formation between cyclodextrin 
and the guest molecule, chemical shift changes in NMR spectra of both the host and the guest 
molecule protons occur due to weak nonbonding interactions. 105-116  Binding constants can be 
calculated using these changes in chemical shifts, which ultimately gives a researcher useful 
information regarding the stability of the formed complex, as well as unique structural 
information.105-108 Given the fact that each glucose unit of the host CD molecule has five chiral 
centers, CD cavities have a chiral environment. This ensures that the formation of an inclusion 
complex with a racemic mixture of a chiral guest molecule will ultimately form two 
diastereomeric inclusion complexes.61  Again, in such instances, NMR spectroscopy has been a 
useful tool in the investigation of chiral recognition properties of CD cavities.109-114  For example, 
from the change in chemical shift, it is possible to determine from which side of the CD cavity 
(the primary hydroxyl side or the wider secondary hydroxyl side) the guest insertion occurs, as 
well as the depth of penetration of the guest molecule insertion into the CD cavity.106,107,114,115 
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1. 4 Chirality and Cyclodextrin Recognition 
 A chiral molecule, defined as a molecule that is not superimposable on its mirror image, 
exists as a pair of stereoisomers.  These two stereoisomers, or enantiomers, are structurally 
identical and have the same physical properties.  They do differ, however, in their three-
dimensional spatial arrangement, and have no planes of symmetry.  The accepted designation for 
these sterioisomers is commonly known as R and S.  
 When a plane of polarized light is passed through a sample of each enantiomer, one will 
rotate the light to the left ((-)-enantiomer), and the other to the right ((+)-enantiomer).  If the light 
was passed through a 50:50 mixture, no rotation would be observed and this mixture would be 
considered racemic and optically inactive. Classically defined, a racemic mixture is a mixture of 
the two enantiomers in equal proportions. 
           Diastereomers are stereoisomers that are not mirror images. Two diastereomers are 
different compounds, and have different relative stereochemistry and different physical 
properties. 
 
1.5 Optical Activation 
        There are two general approaches used in the production of nonracemic chiral organic 
compounds (optical activation): 117 (i) resolution of enantiomers from the racemic solution; and 
(ii) asymmetric syntheses, involving chemical or enzymatic procedures using either chiral or 
achiral reagents.  Both methods used in the preparation of enantiomerically pure compounds are 
very expensive and time consuming.  
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1.6 Resolution of Enantiomers  
        Enantiomeric resolution from racemic mixtures can be done in two ways: they include (1) 
the crystallization of enantiomers from racemic solutions without using resolving agents and (2) 
resolutions by diastereomeric complex formation.117  
 
1.6.1 Diastereomeric Inclusion Complex Formation 
         Separation of enantiomers from racemate solution is called resolution. Enantiomers can not 
be resolved easily from solution because they have the same physical and chemical properties. 
Difference in properties can be achieved by derivatisation with some optically active compounds 
like cyclodextrins and form diastereomeric complexes. Separation of a racemate into a mixture 
of diastereomers through the formation of inclusion complexes is a very well known approach 
used in the resolution of compounds from a mixture. Schlenk118 first used the inclusion method 
for resolution in 1965. Inclusion compounds can be divided into two broad classes: (a) the 
cavitates119 in which the guest molecule is partially or entirely enclosed within a host molecule 
(e.g., cyclodextrins, crown ethers 1-4) (b) clathrates, in which the guest molecules are 
surrounded by host molecules.120   In cavitates, inclusion of one enantiomer of amino acid 
derivatives  (e.g. 5-11) in the cavity of racemic cyclic crown ethers121 (e.g. 1-4) leads to 
crystallization of only the more stable diastereomeric complex in enantiomerically pure form.122-
124  Different stability and solubility of diastereomeric complexes could lead one of the 
diastereomeric complexes to crystallize out selectively from the racemate solution more rapidly 
than others and as a result, this approach can be used for the enantiomeric resolution. The desired 
enantiopure guest compound can be recovered using dissolution, or extraction of the 
diastereomeric complex.117                                                                                                   
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The first chiral macrocyclic compounds were reported by Cram and co-workers in 
1973.125  Subsequently, many chiral macrocyclic compounds have been synthesized and tested 
with respect to their ability to function as hosts of inclusion complexes with many different 
chiral amino acid guest compounds. Along with enantiomeric resolutions of guests, enantiomeric 
resolution of hosts using the chiral guest  have also been observed in liquid-liquid and liquid-
solid chromatography.126-130 Chiral recognition of amino ester salts from aqueous solution to 
organic solvent by various macrocyclic hosts has been attempted.131,132   
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       The extent of chiral recognition has been determined for the complexation between seven 
chiral amino acid perchlorates (5-11) and four macrocyclic polyether hosts (1-4) containing 
chiral elements by Cram and coworkers.122  It was found that host 1 formed a more stable 
diastereomeric complex (RR)(D) with the D-enantiomer of all seven amino acid perchlorate 
guests while hosts 2, 3, and 4 preferentially form stronger diastereomeric inclusion complexes 
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(SS)(L) with the L-enantiomer. Hosts such as 2, which contain two chiral elements, provided the 
highest chiral recognition in complexation. The two methyl groups of 2 extended the chiral 
barriers of the naphthalene rings and provided greater binding with the guest. Many other 
researchers have modified multi-heteromacrocycles by adding different functionality such as 
saccharides,133-135, tartaric acid136-138, 9,9’-spirobifluorene123  to improve their ability as hosts for 
chiral recognition. 
       Recently Nohira139 and co-workers have studied chiral recognition ability of optically pure 
molecules 12 and 13 with different chiral amines 14-18 in solution using 1H NMR titration 
method.  
NHCOPh
COOH12 13
NH
CH3 NH2
CH3
NH2
CH3CH3
NH2
14 15 16 17 18
H
H
NHCOPh
COOH
H
H
 
 
        It was proposed that endo-3-benzamidonorborn-5-ene-2-carboxylic acid 12 can be used to 
resolve 14, while chiral resolution of chiral amines 14-18 was unsuccessful using optical pure 13. 
It was demonstrated that the additional CH-π interactions between the vinylic hydrogen atom of 
12 and aromatic ring of 14 provided extra stability to the formed structure which resulted in 
optical resolution. Both optically active 12 and 13 showed chiral recognition with chiral amines 
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14-18. The chiral recognition ability also increases as the aromatic feature of the amines 
increases, which indicates that the π-π interaction should be the major factor. 
1.6.2 π−π Interaction in Complex Formation 
        The non-bonding interactions between electron rich and electron poor aromatic compounds 
play a very important role in chiral recognition through diastereomeric complex formation.140-142 
Aromatic interactions are important contributors in protein folding and structure. 143-144 Recently, 
the role of aromatic π−π interactions has been investigated  in α-helix and β-hairpin structures 
by Waters.145 Chiral discrimination through nonbonding interactions between π-electron poor 
aromatic compound 19S and π−electron rich aromatic compound 20 has been studied146 using 1H 
NMR and IR spectroscopy.  
O2N
O2N
O
HN
CH3
Ph
H3CO
H3CO
H3CO
CH3
OAc
19S 20    
     
           For example, the 1H NMR spectra of racemate 20 showed only one set of signals for both 
enantiomers. In the presence of template 19S, two sets of signals were obtained, each from 
different enantiomer and in ratio according to the enantiomeric composition. This clearly 
supports the formation of two diastereomeric complexes of 19S with each enantiomer of 20, 
which have different properties. The IR spectra of the complex also supports the presence of 
diastereomeric nonbonding π-π interactions between the electron rich and the electron poor 
compounds. 
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1.7 The Emergence of Chiral Drugs in Pharmaceutical Industries 
       Drugs such as quinine (21) and morphine (22) are isolated from natural resources as single 
enantiomers. But the synthesis of these natural products in a laboratory setting has yielded 
racemic mixtures of these important pharmaceuticals.  Obtaining the desired enantiomerically 
pure compound from the racemate is challenging both in the development of new stereoselective 
drug manufacturing and the affordability of the production of such compounds. Until recently, 
many commonly used therapeutic agents marketed by pharmaceutical companies have been 
synthesized and utilized as racemic mixtures. However, with the emergence of new technology, 
as well as the discoveries of potentially disastrous side effects from the unwanted enantiomer, 
there has been a scientific drive towards the development of enantiomerically pure drugs.147 
N
HO
H3CO
N
H
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O
HO
HO
H
N
CH3
morphine (22)  
 
       When therapeutic agents accumulate in the body, they react with specific binding sites and 
these binding sites have specific physical shapes. If a chiral racemic mixture of a drug has been 
used, then both enantiomers of the drug compete with each other to fit into the active site of the 
receptor. There are several drawbacks to this. Usually, one isomer binds preferentially while the 
other has little or no activity and many times it causes some serious side effects. Furthermore, 
since the biological messenger molecules and cell surface receptors that medicinal chemists 
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target are chiral, ideally synthetically designed drugs should match this asymmetry.  
Pharmaceutical industries are now switching from currently marketed racemic drugs into more 
active single isomer drugs, or more preferably, they are targeting the development of safe drug 
delivery systems that will be capable of carrying only the biologically active enantiomer of the 
racemic drug to the targeted biomolecule.  The 1999/2000 annual sales of chiral drugs were 
reported being close to one-third of all drug sales worldwide.148  The top two best selling drugs, 
Lipitor (23) and Zocor (24), with combined sales of almost $14 billion in 2002 are single-
enantiomer drugs. Lipitor is the most popular drug ever sold in  history. In 2002, worldwide sales 
of single-enantiomer drugs reached more than $159 billion.  
N O
HO HO
O
HN
O
F
Ca2+
2Lipitor (23)
H
O
O
O OH
CH3
H3C
O
H3C
H3C CH3
Zocor (24)     
                                                                                                      
   Many of the pharmaceutical companies are switching from marketing racemic compounds 
to optically pure drugs.  For instance, AstraZeneca and Wayne’s racemate proton pump inhibitor 
omeprazole (25) (brand name: Prilosec/Losec). Clinical trials show that the biological activity 
comes only from the (S)-enantiomer.149 This company has patented the (S)-isomer separately150 
as esomeprazol (brand name: Nexium). It is prescribed for healing ulcers by preventing secretion 
of gastric acid. Clinical trial results show that more patients with erosive esophagitis and 
heartburn were healed with esomeprazole than with omeprozole. Economically, it is more 
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feasible to develop a general procedure that can “extract” only one enantiomer of the racemic 
drug and later on deliver it to the targeted biomolecule. 
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  Racemic drug Prozac (26) (generic name: Fluoxetine), is one of the best selling drugs 
marketed by Eli Lilly. Its both enantiomers are nearly equipotent as inhibitors of serotonin 
uptake but the (S)-isomer has a longer washout period.  Furthermore, its nor (N-demethyl) 
metabolite is much more potent than (R)-norprozac and accumulates on long-term treatment.151  
(R)-prozac is essentially a single active moiety and has the potential to provide a shorter washout 
period and, hence, greater flexibility for treating depression. Recently this company has received 
clearance from FDA to market (R)-prozac for the treatment of bulimia nervosa, an eating 
disorder that afflicts more than 1 million Americans each year. 
    Another very important racemic drug is zopiclone (27), originally developed and marketed 
by Rhone-Poulec Rorer. The biological activity of zopiclone (27) come from its metabolite, (S)-
desmethylzopiclone (28), in which an N-methyl piperazine has been demethylated. 152  Due to the 
fact that the prodrugs can compete with one another for the same enzyme site which metabolizes 
them, all marketed prodrugs should be used as one pure enantiomer. Such competition can lead 
to unfavorable drug interactions if one drug ties up the available enzyme and the other drug 
builds up to excess levels in the blood.  
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        Other disaterous incidences occurring from the use of racemic mixtures of drugs include 
perhexiline (29). This racemic drug was prescribed to control abnormal heart rhythms. In the 
1980’s, many people died because of accumulating this racemic drug. After thorough research on 
the metabolism of this drug, it was discovered that the R enantiomer of perhexiline, which had a 
much longer half-life and more slowly metabolized, was responsible. According to Caldwell,147 
it is true that racemic drugs can cause problems because of the different biological activity of 
both enantiomers, but they can also cause serious problems due to difference in the 
pharmacokinetics as well. Many lives might have been saved if the enantiomerically pure drug 
had been given to patients instead of the racemic form of perhexiline (29). 
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        Other examples include the (S)-enantiomer of the anti-arthritic compound penicillamine 
(30), which is responsible for the biological activity, while the (R)-enantiomer of this drug is 
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extremely toxic. The (S,S)-form of ethambutol (31) is a tuberculostatic agent but the (R,R)-form 
can cause blindness. The Parkinson’s disease drug dopa (32) is marketed in an enantiomerically 
pure (L-dopa) form because the D-form causes serious side-effects such as granulocytopenia (a 
loss of white blood cells that leaves patients prone to infections). 
         New single stereoisomer drugs have proven to be safer, exhibit fewer side effects, and are 
more potent than their racemic counterparts. For instance, enantiomerically pure drugs are able 
to affect the desired process as does the racemic mixture of the same coumpound, yet typically, 
lower doses of enantiopure compounds are administered to patients due to the fact that the 
absorption and uptake of desired enantiomers is not hindered by the competitive binding of the 
unwanted enantiomer.  Additionally, potential life threatening side effects elicited by the 
administration of the unwanted enantiomer through the racemate are also eliminated by using 
enantiopure compounds. According to the FDA (Food and Drug Administration, USA), new 
optically active drugs should be prepared for marketing in their enantiomerically pure form.153        
 There are two approaches commonly used to prepare single stereoisomer compounds.  
These approaches include (i) synthesis of a desired enantiomerically pure product using either 
chiral intermediates or chiral catalysts and (ii) separation of enantiomers from racemic mixtures 
using chiral separation techniques.  While relatively successful, both approaches tend to be very 
expensive and often cause added difficulties in both preparation and separation methods. To 
sidestep each of these drawbacks, researchers in this field are beginning to address the issue of 
the production of enantiopure compounds by developing new chemical techniques, namely chiral 
drug delivery systems. These drug delivery systems can address each of these problems and 
allow either inexpensive preparation procedures for the production of racemic products or use 
already developed synthetic procedures for the preparation of racemic mixtures of active 
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therapeutics. By using simple and inexpensive methods of purification the desired 
enantiomerically pure targeted compound can be isolated in high yield and high optical purity 
from the mixture. 
 
1.8 Cyclodextrins as Drug Carrier 
          The ideal drug delivery systems for such a task have to fulfill some requirements. The 
system has to deliver the necessary amount of compound to the receptor or the targeted binding 
site in an efficient and precise manner.154-156  Suitable carrier molecules (hosts) must be used to 
overcome undesirable properties commonly associated with biologically active compounds, such 
as stability and solubility in aqueous media. Many pharmaceutical drugs on the market today, as 
well as potential drugs undergoing clinical trials, have relatively low water solubility; as a result, 
these are usually administered in substantially higher doses than required with the common idea 
being that the excess of the drug will be secreted from the body without any side effects.  This, 
however, is not always the case and in many instances the excess drug is responsible for adverse 
side effects.  In many cases co-solvents (usually alcohol) are used to increase drug uptake. 
However, there are examples throughout the literature that indicate that cyclodextrins, one 
example of a chiral host system, can form inclusion complexes with a variety of compounds, 
provided the guest is able to fit inside the cyclodextrin cavity.157  There are two benefits for using 
cyclodextrins as chiral drug carriers.  The first is a decrease in toxicity158 and an increase in the 
water solubility, stability, and bioavailability of the drug. The second is the selective chiral 
delivery of only one enantiomer of the starting racemic mixtures.  Considering these favorable 
properties, cyclodextrins can be used as an additive in the marketed drug. Additional advantages 
include the fact that CDs can be chemically modified, which in turn can increase guest-host 
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interactions and enantioselectivity.  For example, chemically modified cyclodextrin derivatives 
have been prepared to enhance the physiochemical properties and inclusion capacity of natural 
cyclodextrins as drug carriers.159-166 Cyclodextrins can also form stable complexes with a variety 
of drugs including prostaglandins, barbiturates, steroids, and nonsteroid anti-inflammatory 
drugs.167       
 
1.9 Chiral Recognition by Native Cyclodextrins 
 All reactions that take place in living cells are catalyzed by enzymes. Enzyme mediated 
chemical transformations are stereospecific. Therefore, there is no need for nature to develop 
methods of enantiomeric separation. Enzymes preferentially bind one enantiomer over other. 
Examples include enzymes that synthesize most proteins preferentially bind only L amino acids, 
while enzymes that metabolize sugars bind only D sugars.168 Racemic substrates can be used in 
enzyme catalyzed reactions, and in such cases only one enantiomer will be incorporated into the 
product. Unfortunately, enzymes cannot be used as resolving agents of enantiomers from 
racemates, because they are pH, temperature and solvent dependant and are not easy to handle in 
laboratory settings. It is also difficult to isolate enzymes from nature in an amount that can be 
used in organic synthesis. Thus, synthetic organic chemists are drawn to small organic 
compounds which can mimic some of the properties of enzymes and can be used as resolving 
agents. One of these compounds is cyclodextrin.  
          CD inclusion complexes made with a variety of guest compounds can be used as a 
method of chiral resolution, but the exact nature of the interaction between the CD and the guest 
molecule, which leads to enantiomeric discrimination, is still not known in detail. It is widely 
accepted that various forces,169-172such as hydrogen bonding, Van der Waals’ forces, 
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hydrophobic interactions, and π−π interactions173,174 contribute to the complex formation. Since 
cyclodextrins are capable of forming stable inclusion complexes in aqueous solution with a 
variety of aromatic compounds,175-178  it is reasonable to propose that cyclodextrins can form 
diasteriomeric inclusion complexes with racemic aromatic compounds. Based on the knowledge 
that diasteriomers have different physical properties, it is reasonable to expect that one of the 
diasteriomeric inclusion complexes will crystallize out from the racemic aqueous cyclodextrin 
solution more readily than the other. It has been well demonstrated throughout the literature that 
in the case of conglomerates, once one of the enantiomers starts to crystallize from the solution, 
it is possible to obtain high optical purity of this enantiomer.179  It is also well demonstrated that 
better chiral discrimination is obtained with molecular systems, such as cyclodextrins, that have 
many chiral centers.  
        Armstrong180-182 summarized the requirements for chiral recognition and stereoselective 
binding with β-CD, and these requirements also hold true for α- and γ-CD. 
(a) An inclusion complex must be formed. 
(b) There must be a tight fit of the included moiety within CD. 
(c) The chiral center of the guest or a substituent of the chiral center (e.g., a carboxylic acid 
group) must be able to form at least one strong interaction with the hydroxy groups on the 
surface of the CD cavity.   
         Cramer and Dietsche first proposed the use of cyclodextrin inclusion complexes with a 
variety of guests with β-CD for resolution of guest enantiomers from racemates.183 Mularz and 
coworkers have reported the importance of hydrogen bonding between the guest and 
cyclodextrin during the complex formation.184 They proposed that all four isomers of adrenergic 
drug ephedrine (33) and pseudoephedrine (34) form inclusion complex with β-cyclodextrin.The 
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ammonium group of these drugs form hydrogen bonds with secondary hydroxyl group of β-CD 
while the hydroxyl groups form hydrogen bonds with either ether oxygen or primary hydroxyl 
oxygen atoms. The (S,S)-form of pseudoephedrine was resolved from mixture of diastereomers 
by using β-CD mobile phase.  
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          Li and co-worker Purdy185 studied stability and structure of the inclusion complexes of β-
cyclodextrin with dinitro phenyl (DNP) amino acids (DNP-valine, DNP-leucine, and DNP-
methionine) (Figure 1.4). They proposed the necessity of side chain interactions between β-CD 
and amino acids to form inclusion complexes, which leads to chiral discrimination. 
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Figure 1.4 Structures of inclusion complexes of β-cyclodextrin with DNP-D- valine and with 
DNP-L-valine.  
 
 
        Figure 1.4 clearly shows the chiral discrimination of the two enantiomers of DNP-valine 
amino acid in forming inclusion complexes with β-CD. It was found that in all three DNP-amino 
acid’s inclusion complexes with β-CD, the dissociation constant for L- enantiomers has always 
lower than that of D-enantiomers.  The dinitrophenyl group, which is the hydrophobic part of the 
amino acid studied, enters the β-CD cavity from the wider secondary hydroxyl rim and forms a 
stable inclusion complex. The large chemical shift change (∆δ) of H-3 and H-5 protons of β-CD 
(figure 1.5) during complexation indicates that the DNP group of amino acid is inside β–CD 
cavity. Also, the larger ∆δ value for the 5′ proton in the presence of DNP-D-valine compared to 
DNP-L-valine indicated the deeper penetration of DNP group inside β-CD cavity.185 The alkyl 
group of DNP-amino acid plays a very important role in chiral recognition between two 
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enantiomers. The alkyl groups of DNP-L-amino acids form 1:2 inclusion complexes with the β-
CD cavity, whereas in the case of DNP-D-amino acids a 1:1 complex is formed due to steric 
repulsion of alkyl groups with the CD hydroxyl group. The shallower insertion of the DNP-L-
amino acid leaves enough space in the β-CD cavity to host the alkyl group from another DNP-L-
amino acid. 
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Figure 1.5 Localization of the “external” and “internal” protons in β-CD 
 
            The crystal structures of the complexes of β-CD with the anti-inflammatory,167 
antipyretic, and analgesic agent fenoprofen (FP), determined by Hamilton and Chen, also 
provide a good example of cyclodextrins acting as a resolving agent in racemic mixtures. 
Fenoprofen, a racemic drug developed at Eli Lilly, has two optical isomers, (R)-(-) and (S)-(+). 
On the basis of 50% inhibition of the fatty acid cyclooxygenase system, the S stereoisomer was 
found to be 2 times more potent than the racemate and ~35 times more active than the R 
stereoisomer. 186 This provides another very good example of the importance of enantiomerically 
pure drugs.  
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Figure 1.6 ORTEP plot of dimer β-CD-(S)-fenoprofen complex (head to tail packing 
arrangement) 
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Figure 1.7 ORTEP plot of dimer β-CD-(R)-fenoprofen complex (head to head packing 
arrangement) 
 
 
         In the crystal, the two FP-β-CD complexes exist in such a way that the two β-CD 
molecules face their wider opening side (which contains secondary hydroxyl groups) in a head to 
head manner. One fenoprophen guest molecule is inserted in the cavity of each β-CD monomer 
forming a 1:1 complex.187 In the crystal structures of FP-β-CD complexes, the packing 
arrangement of each isomer of fenoprophen is different.  For example the two independent 
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fenoprophen guest molecules R1 and R2 of the R complex are oriented in the β-CD cavities with 
their phenoxy groups pointing toward the wider rim end of the CD, giving an antiparallel or 
head-to-head arrangement, while those of the S complex pack in a parallel, or head-to-tail, 
manner. This is unexpected considering the hydrophobic cavity of cyclodextrin. It is proposed 
that steric factors are responsible for the unusual packing arrangement of S-complex. Both 
carboxylic acid groups of the (S)-fenoprofen form strong H-bonds with hydroxyl groups of β-
CDs in (S)-FP-β-CD complex, while in (R)-FP-β-CD complex, both carboxylic acid groups form 
hydrogen bonds with water alone. This explains 3 times more binding affinity of (S)-FP with β-
CD compared to (R)-FP.158 
         Rekharsky and co-workers have studied the complexation and chiral recognition behavior 
of γ-cyclodextrin with various enantiomeric and diastereomeric dipeptide pairs.188  They 
proposed that better chiral recognition was found with diastereomeric dipeptides compared to 
enantiomeric peptide pairs. 
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Figure 1.8 Plausible complex structure Cbz-D-Ala-L-Trp with γ-CD 
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         During their complaxation study they proposed that γ-cyclodextrin showed an excellent 
chiral recognition behavior with Cbz-D/L-Ala-L-Trp (35) diastereomer guest pair (Figure 1.8). 
For instance, the D,L-isomer pair of this dipeptide showed more than seven times higher affinity 
toward γ-CD compared to L,L-isomer. This affinity enhancement for D,L-isomer is entropy 
driven. From NOE cross-peak results (Figure 1.8), it was proposed that upon complexation, the 
large size of indole ring prevents it from rotation and thus it change the depth of penetration by 
sliding parallel to the γ-CD cavity axis. NOE three space coupling interaction from ROESY 
spectra indicates interaction between indole ring hydrogens (Hb-He) and Cbz’s Ho, Hm and Hp 
with γ-CD cavity walls. This is also indicates the stacking of indole/Cbz rings inside cavity. 
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     There is a small difference in association constants of two isomers of Cbz-Gly-Phe (36), 
bacause the long flexible tether is conformationally restricted upon stacking.188 When Gly is 
replaced with rigid Pro residue, which provides less conformation of the tether, gives higher 
chiral discrimination. The D,L-isomer of Cbz-Pro-Phe (37) provides more than five times higher 
affinity compared to the L,L-isomer, because only D,L-isomer perfectly fits into the CD cavity, 
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giving higher chiral discrimination. The large negative entropy and large negative enthalpy of 
complaxation also indicated the improper fitting of L,L-isomer into γ-CD cavity. 
 
1.10 Chiral Recognition by Modified Cyclodextrins 
       In native cyclodextrins (α-, β- and γ-CDs), the glucopyranose units are symmetrically 
arranged. This higer symmetriy of native cyclodextrins is often responsible for their poor chiral 
recognition. There are many examples in literatures indicate the improvement of chiral 
recogniton by using functionalized cyclodextrins which are prepared by chemical modifications 
of native cyclodextrins.159-166  It is proposed that mono and diaminated β-cyclodextrins can 
provide better enantiomeric recognition compared to native β-CD.189-191 The higher chiral 
recognition ability of these modified cyclodextrins is attributes to the three-point interaction.192 
The three-point interaction was originally proposed by Easson193 to explain chiral recognition of 
two enantiomers of a drug. Enantiospecific conversion of a prochiral reactant to chiral product 
by enzymes was explained by this three-point interaction by Ogston. 194 Recently, Liu and co-
workers proposed that binding of Quinine (38) and Quinidine (39) can be enhanced in great 
extent by using mono(6-deoxy-6-{[(R)-1-(hydroxymrthyl)propyl]amino})-β-cyclodextrin (40) in 
contras to native β-CD. 195  
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       In this chirally-modified β-CD host molecule (40), one of the primary hydroxyl group in 6-
position is replaced by chiral [1-(hydroxymethyl)propyl]amino substituent. The enhanced 
diastereoselective recognition ability of (40) is attributed to this modification, which provides 
stronger Van der Waals, hydrophobic and additional hydrogen bonding interactions between host 
(40) and the guest molecules Quinine (38) and Quinidine (39). The Ka values for the 
complaxation of (38) and (39) with (40) were determined to be 84200 and 27300 Mol-1, 
respectively, which corresponds to a diastereoselectivity of ca. 3:1. 
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1.11 Terpenoids 
        For the past century, scientists have been using isolation techniques to extract many 
organic compounds commonly considered “natural products” from plants, mainly using steam 
distillation and stepwise extraction methods. These odoriferous or flavoring volatile oily plant 
extracts are called essential oils, and have been used in medicines, spices and perfumes. Such 
plant essential oils consist of a mixture of lipids, known as terpenes. Terpenes were originally 
named after turpentine, the volatile oil extracted from pine trees. Terpenes containing oxygen 
atoms are usually referred as terpenoids. Terpenes are classified according to the number of 
isoprene units they contain. Most terpenes have skeletons of 10, 15, 20 or 30 carbons. 
Terpenoids with 20 carbons are referred as diterpenoids. 
 
1.12 Dolabellane Diterpenoids 
         Dolabellane diterpenoids, obtained primarily from marine sources, share the unique 
feature of a trans-bicyclo[9.3.0]tetradecane nucleus and in many cases, exhibit antimicrobial, 
antitumor and antiviral activities.196-198 The remarkable biological activity of most dolabellane 
diterpenoids prompted research for the total synthesis of various dolabellane diterpenoids. There 
are many literature available on synthetic studies199-208 of dolabellane diterpenoids as well as 
their total synthesis.198,209-213 Dolabellane diterpenoid 41 (figure 1.9) from sea hare was initially 
isolated by Faulker et al. in 1976 from the opistobranch mollusk Dolabella californica at Isla 
Partida, Gulf of California.214 
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AcO
HO
41  
                                     Figure 1.9 First isolated dolabellane diterpenoid 
 
        Okinawa sea waters have been recognized as rich sources for marine natural products, 
including the soft corals of genus Clavularia. Most of these natural products show remarkable 
biological activities. It was found that Clavularia viridis, a marine plant, has a rich source of 
prostanoids215-221 and steroids222-226. Many other terpenoids227-232 were also found from other 
species of Clavularia, such as C. koellikeri.233 
        Many Dolabellanes exhibit significant antitumor activity, and in vivo potency against the 
influenza virus and adenovirus and nearly all dolabellanes possess antimicrobial activity against 
bacteria.208 Dolabellanes have also been discovered in the brown seaweeds of Dictyotaceae,234-
235 the sea whips of Eunicea,236-237 the liverwort Odonttoschisma denudatum,238 the mollusk 
Aplysia dactylomela,239 and soft corals of Clavularia.240-241 Dolabellane diterpenoids are 
chemical precursors of fusicoccanes (a group of diterpenoids known for significant biosynthetic 
plant growth regulators242). Dolabellanes (such as 42 Figure 1.10) also serve as biogeneric 
precursors of 5-7-6 tricyclic terpenes of the dolastanes (a class of marine natural products). 
198,208,243,244 
29
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Figure 1.10 Dolabellane diterpenoid 42 
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1.13 Isolation, Purification and Biological Activity of Dolabellane Diterpenoids 
         Two new diterpenoids, B and D, as well as two known diterpenoids A (dolabellatrienone) 
and C (claenone), having a dolabellane skeleton (trans-bicyclo[9.3.0]tetradecan) were recently 
isolated from the Okinawan soft coral of the genus Clavularia by Iguchi and co-workers (Figure 
1.11) using the following methodology:233 
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Figure 1.11   Isolated dolabellane diterpenoids A, B, C and D 
 
          The MeOH extract of wet specimens (1.1 kg) was partitioned between ethyl acetate and 
water. An EtOAc-soluble portion (18.9 g) was obtained by concentrating the organic layer under 
reduced pressure, from which 10 g of crude material was chromatographed on a silica-gel 
column. Stepwise elution with solvents of increasing polarity (hexane, hexane- EtOAc (4:1), 
EtOAc, and MeOH) was used to collect four different fractions from the crude sample. Stepwise 
further purification of fraction 2 (3.5 g) with silica-gel column using hexane- EtOAc in 10:1 ratio 
gave seven samples, among which only samples 2 and 3 were saved. Reversed-phase HPLC 
(eluted with MeOH-H2O = 9:1) of sample 3 (142 mg) gave compound A (30 mg). Compound B 
was obtained by purification of sample 2 (340 mg) in two steps (i) flash chromatography (eluted 
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with hexane-2-propanol = 20:1) and then (ii) normal phase HPLC (eluted with hexane-2-
propanol = 30:1) gave 48 mg of compound B.233 
           Fraction 3 (6.0 g) was chromatographed on a silica-gel column using EtOAc as the mobile 
phase. 1.0 g of fraction 3 was again chromatographed with hexane-EtOAc (4:1), which gave five 
samples. Further repeated purification of sample 1 (599 mg) with flash chromatography using 
hexane-EtOAc (5:1) gave compound C (273 mg) and D (96 mg).233  
          Compound A was identified as dolabellatrienone,245 which was previously isolated from 
the Caribbean gorgonian octocorals Eunicea calyculata and Eunicea laciniata.246 The absolute 
stereochemistry of dolabellatrienone was specified by previously reported247 synthesis. 
Dolabellatrienone A has been shown to express weak cytotoxic activity toward human colon 
(HCT 116) cell line (IC50 10 µM).248 Compound C was identified as claenone,206,239 found from 
the Okinawan soft coral of the genus Clavularia.  Claenone C has been shown to express 
ichthyotoxic activity toward killifish Oryzias latipes (minimum lethal concentration: 10 
µM/mL)231 and potent cytotoxic activity toward human prostate cancer WMF (GI50 2.42x10-7M) 
and RB cells (GI50 3.06x10-7M).246 Claenone C was found to gradually oxidize to D at room 
temperature in an ethyl acetate solution. This change is due to oxidation of the double bond at C-
7 of Claenone C. If the ethyl acetate solution of C was stirred at room temperature under an 
atmosphere of O2, 37% of C converted to compound D. This suggests that Compound D is not 
actually extracted from the soft coral of the genus Clavularia, but rather formed from C during 
the isolation process.233 Compound D showed moderate cytotoxic activity against ovarian 
cancer, colon cancer, lung cancer, and stomach cancer cells.249 
        The molecular formula of C20H32O for B was determined233 by elemental analysis and the 
13C spectrum. DEPT experiments and 13C NMR spectrum indicated the presence of five methyls, 
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seven SP3 methylenes, two SP3 methines, two SP3 quarternary carbons, one SP2 methine and 
three SP2 quarternary carbons. With the help of 1H and 13C NMR spectra, the presence of a 
trisubstituted epoxide, a trisubstituted double bond, a tetrasubstituted double bond and three 
olefinic methyl groups was identified.233 
 
 
Figure 1.12   Perspective view (ORTEP) of B 
 
         The single crystal of B was grown and X-ray crystallographic analysis was carried out to 
obtain the relative stereochemistry of the four chiral centers (C-1,-3,-4 and -11) as well as the 
stereochemistry of the trisubstituted double bond.233 The results of the X-ray analysis suggest the 
1S*, 3R*, 4R* and 11S* relative configurations for the four chiral centers as well as the E 
configuration for the trisubstituted double bond (C7-C8).  
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II. Cyclodextrin Assisted Chiral Recognition of Amino Acid Imides 
 
 Resolution of enantiomers can be accomplished by using stereoselective cyclodextrin co-
crystallization or precipitation of one enantiomer from a water solution of racemic compounds. It 
has been projected in the literature that stronger enantiomeric recognition can be accomplished if 
two enantiomers compete for binding into multi-chiral resolving molecules, such as chiral crown 
ethers or cyclodextrins.250  Cyclodextrins can form inclusion complexes with a variety of amino 
acids that fit inside the cavity of cyclodextrin. Nonbonding interactions, such as hydrogen 
bonding, electrostatic interactions, hydrophobic interactions, π-π-aromatic stacking, dipole-
dipole interactions between cyclodextrins and amino acids  are  responsible for the complex 
formation, as well as for the formation of molecular associates.251,252  Aromatic π-π stacking 
interactions between electron poor and electron rich moieties are crucial for the formation of 
molecular associates, interactions between substrate and enzymes, biomolecular associates, 
organic molecule conformation, etc.253-257  Multi-point interactions, which are interactions 
between diastereomeric complexes and ligands with many chiral centers such as cyclodextrins, 
are very important for enhanced enantiomeric recognition.258 
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2.1 Amino Acid Imide Guest Compounds with One Chiral Center 
 
2.1.1 Cyclodextrin Assisted Formation of Homochiral Polymer-like Associate in One 
Chirality System 
 
 The proposed formation of self-assembly259 and cyclodextrin assisted molecular 
associates are presented in Figure 2.1.260  Molecule M has four moieties (a polar carboxylic 
group, a chiral center, electron poor and electron rich aromatic moieties) that should be essential 
for the formation of homochiral polymer-like molecular associates.  The two aromatic moieties 
(electron poor and electron rich) of two different M molecules enable them to form self assembly 
molecular associates 2M through π-π stacking. The π-π stacking of aromatic complexes are very 
weak, and therefore these molecular associates should be stabilized by binding into the 
cyclodextrin cavity thus forming the ternary inclusion complex 2M-CD (Figure 2.1). In this 2M-
CD complex, two aromatic moieties, each from different M molecules, can now form a new 
cyclodextrin inclusion complex and molecular associate with a new M molecule.  In such a way 
the polymer-like molecular associate would be formed. 
  The polar groups of these associates, such as carboxylates, interact with water molecules 
by forming hydrogen bonds.  On the other hand, the chirality of M makes the molecular 
associate diasteriomeric and stereoselective for incorporating new enantiomer of M into the 
homochiral molecular associate. 
  35
do
no
r
accep
tor
OOC
OOCM
OOC
+ CD
2M-CD complex
OOC
OOC
OOC
homochiral
polymer-like
associate
OOC
OOC
2M
+M
- M
2M-CD
CD
- CD
OOC
+ nCD
+ n(2M-CD)
- nCD
- n(2M-CD)
4M-3CD complex
 
Figure 2.1   Possible pathway to cyclodextrin assisted formation of homochiral polymer-like 
associate. 
 
 
2.1.2 Benzo[de]isoquinoline-1,3-dione Derived Amino Acids 
 The proper molecular system must be selected to test the validity of the proposed 
cyclodextrin assisted self-assembly approach to enantiomeric recognition.  Amino acids are the 
best molecular choice for this study, because they are an abundant source of chiral molecular 
systems in organic chemistry. Since the majority of them do not form strong inclusion complexes 
with cyclodextrins, introducing both electron-rich and electron-poor aromatic moieties through 
simple chemical modifications of natural amino acids seemed appropriate to perform the 
proposed studies.  For instance, three aromatic compounds, with noticeable difference in 
aromatic electronic properties, are methylindole, toluene, and methylbenzoisoquinoline-1,3-
dione (Figure 2.2).  The AM1261 computed frontier molecular orbital (HOMO-LUMO) energies 
suggest that of these three molecules, toluene is electronically neutral, indole is electron rich and, 
benzoisoquinoline-1,3-dione is electron poor (Figure 2.2). These moieties are incorporated into 
amino acids to accomplish the requirements to study the proposed formation of molecular 
associates. 
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Figure 2.2 The AM1 estimated HOMO-LUMO energies for the aromatic moieties 
 
 To show the formation of molecular associates discussed in Figure 2.1, three amino acids 
were selected: alanine (no aromatic moiety), phenylalanine (aromatic electronic properties), and 
trypthophan (electron-rich aromatic electronic properties).  Through amino group replacement 
with benzo[de]isoquinoline-1,3-dione (Figure 2.2), new molecular systems 30a, 30b, and 30c 
were generated (Figure 2.3).  These three molecules have the same electron poor aromatic 
moiety; therefore the LUMO orbital energy for all is similar while big differences exist in the 
HOMO energies. The AM1 estimated LUMO-HOMO energy difference, as measured for π-π 
aromatic stacking capabilities, are 8.00 eV, 7.85 eV, and 7.69 eV for 30a, 30b, and 30c, 
respectively. Since guest compound 30c has the lowest LUMO-HOMO energy gap, it is 
expected to form the most stable π-π molecular stacking that can be also complexed with 
cyclodextrins. 
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Figure 2.3 The AM1 estimated HOMO-LUMO energies for three modified amino acids 
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 The synthetic conditions for the preparation of these amino acid derivatives are presented 
in Scheme 2.1.  Reactions were performed with the amino acid and benzo[de]isochromene-1,3-
dione in DMSO as a solvent for the alanine derivative and in pyridine as a solvent for 
phenylalanine and tryptophan derivatives (Scheme 2.1).  The isolated yields range between 80-
95%. 
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Scheme 2.1 Preparation of guest molecules 43a, 43b and 43c 
 
 It is well demonstrated in literature that NMR non-equivalency of enantiomers can be 
observed if one of the enantiomers is present in excess.262,263 To demonstrate the formation of 
self-assembly molecular associates through weak nonbonding interactions between two M 
molecules, spectroscopic studies of racemic and non-racemic highly concentrated solutions of 
43a, 43b, and 43c were studied. 1H NMR spectra of the S and R enantiomers of all three 
compounds at different concentration (0.0001 to 0.3 M) and different molar ratio (1:10, 1:5, 1:1, 
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5:1, and 10:1) were recorded in DMSO, but we were not able to observe any NMR evidence for 
enantiomeric recognition. 
 The formation of molecular complexes is well studied in water media. The NMR study of 
compounds 43a, 43b, and 43c can not be performed in water because of poor water solubilities 
of these compounds.  Therefore, sodium salts of 43a, 43b, and 43c were used for the NMR 
spectroscopic studies.  Neither 43a nor 43b non-equivalence mixtures at any concentration range 
up to 0.1 M and any enantiomeric ratio show spectroscopic difference.  Contrary to this, there is 
NMR enantiomeric nonequivalence of non-racemic 43c (R:S, 1:4 and 4:1) (Figure 2.4).  The 
spectroscopic recognition is not due to the formation of molecular associates through hydrogen 
bonding, nor through electrostatic interactions between the polar carboxylate group and sodium, 
because these interactions are also present in 43a and 43b, and would be observed in the spectra 
of these compounds. The only reasonable explanation is that molecule 43c can form molecular 
associates through π−π stacking between the electronic rich indole and electronic poor 
benzo[de]isochromene-1,3-dione aromatic moieties with the excess enantiomer acting as a 
resolving agent.     
 
 
Figure 2.4 The NMR spectra of aromatic portion of 43c (0.1M) in aqueous NaHCO3 (0.003 M) 
with different enantiomer ratios 
 
   As proposed in figure 2.1, if the π-π stacking interaction of aromatic moieties is 
responsible for enantiomeric recognition, then the NMR spectroscopic recognition can be 
  39
enhanced by cyclodextrin encapsulation (binding). Both aromatic moieties tend to bind into the 
cyclodextrin cavity, and then orient themselves in the proper way for aromatic stacking and the 
formation of strong homochiral molecular associates.  This is perfectly demonstrated in Figure 
2.5 for cyclodextrin assisted enantiomeric recognition of racemic 43c.   
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Figure 2.5 A portion of NMR spectra of racemic 43c (0.001 M) in aqueous NaHCO3 (0.003 M) 
with α, β, and γ-CD (0.01 M), respectively. 
   
         The best enantiomeric discrimination for compound 43c was obtained in γ-cyclodextrin 
by comparison to β-cyclodextrin, while no enantiomeric discrimination was observed in α-
cyclodextrin. These results are not surprising considering that the cyclodextrin cavity must be 
large enough to accommodate two aromatic rings. Although there are some chemical shift 
changes indicating an interaction between α-CD and racemic 43c, it is unlikely that α-CD can 
form a ternary (two molecules and one cyclodextrin) or higher degree cyclodextrin complex with 
the 30c dimer, as shown in Figure 2.6. Enantiomeric discrimination was observed in the NMR of 
43c in γ-CD 
43c in β-CD 
43c
43c in α-CD 
Hf Hd Hc He Ha Hb 
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racemic 43c with β-CD, but was not strong enough to elicit CD enhanced enantiomeric 
separation. We believe this is due to the formation of a “normal” 1:1 complex (Figure 2.6) 
between racemic 43c and β-cyclodextrin. The NMR of racemic 43c in γ-CD clearly shows the 
NMR enantiomer nonequivalence of 43c yielding two sets of peaks, well resolved for both 
enantiomers. γ -CD has the largest cavity of the three studied cyclodextrins; therefore, it can 
form ternary as well as higher order diastereomeric inclusion complexes (Figure 2.6), which can 
provide sufficient spectroscopic differences resulting in NMR discrimination. 
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Figure 2.6.  Possible π-π aromatic molecular complexes between CD and 43c 
 
        A few of the many possibilities in the formation of molecular complexes between amino 
acid imide derivative 43c and cyclodextrins are shown in Figure 2.6. All of these molecular 
complexes are in dynamic equilibrium in aqueous media. NMR spectroscopic study shows the 
average chemical shifts for all of these molecular aggregates.  
   There are two sets of peaks in the NMR of racemate 43c in the presence of γ-CD. It was 
also possible to easily recognize each enantiomer peak, as well as determine the enantiomer 
composition of individual enantiomers by NMR in γ-CD when compared with the racemate 
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NMR in γ-CD (Figure 2.7). If the NMR of racemate 43c is compared with the NMR of 43cR and 
43cS in γ -CD, it can be seen that in the presence of γ-CD, proton signals of enantiomer 43cS are 
more affected compared to that of 43cR. For example, the two triplets are shifted more upfield 
and the singlet is shifted more downfield in enantiomer 43cS compared to enantiomer 43cR in 
the presence of γ-CD. Based on this observation, it might be suggested that γ-CD forms a more 
stable diastereomeric complex with 43cS compared to 43cR. 
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Figure 2.7   A portion of NMR spectra of 43c (0.001 M) in aqueous NaHCO3 (0.003 M) and γ-
CD (0.01 M) 
 
 
  The NMR spectroscopic recognition was not observed in α-cyclodextrin due to the fact 
that neither the indole nor benzo[de]isochromene-1,3-dione aromatic moieties can bind into the 
α-cyclodextrin cavity.  The β-cyclodextrin cavity is sufficiently large to accommodate the indole 
ring.  If there is formation of molecular associates with an order higher than the 1:1 cyclodextrin 
complex with respect to 43c, the electrospray ionization mass spectroscopy (ESIMS) should 
show a molecular peak for each complex. ESIMS spectra of 43cR in presence of β-CD (Figure 
43cS in γ-CD 
43cR in γ-CD 
43c in γ-CD 
43c  
Ha Hb He Hc Hd 
Hf 
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2.8) indicates the formation of 1:1 cyclodextrin inclusion complex formation (1517.4 m/z)  but 
no higher order (1:2 or 2:1) complex between β-CD and 43cR was observed.  
 
 
Figure 2.8 Negative Electrospray mass spectra of 43cR (0.001 mol) in aqueous NaHCO3 (0.003 
M) and β-cyclodextrin (β−CD, 0.01 M) 
 
  The best NMR enantiomeric recognition has been seen with guest compound 30c in γ-CD 
(Figure 2.5).  The electrospray ionization mass spectra of 43c with γ-CD shows the formation of 
2:1 and 1:2 γ-CD complexes (signals at 1488 and 1032, Figure 2.9).  All the other molecular 
complexes are present as well. 
 
 
Figure 2.9 Negative ESIMS of 43cS (0.001 M) in aqueous NaHCO3 (3x10-3 M) and γ-
cyclodextrin (γ−CD, 10-2 M) 
 
 
  Even though 1H NMR and ESIMS spectra show enantiomeric recognition of compound 
30c with β- and γ-cyclodextrin through the formation of molecular associates, they do not 
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provide experimental evidence for the formation of the polymer-like cyclodextrin assisted 
molecular assemblies presented in Figure 2.1. Matrix-Assisted Laser Desorption Ionization 
Time-of-Flight Mass Spectroscopy (MALDI-TOF-MS) spectra analysis of the aqueous γ-
cyclodextrin solution of 43c was performed to demonstrate the formation of the polymer-like 
molecular associates.  The MALDI MS spectra (Figure 2.10) shows typical fragmentation similar 
to the fragmentation of polymers which indicates the structural patterns presented in Figure 2.1. 
All possible fragments were detected with lower intensity for larger molecular fragments (Figure 
2.10). 
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Figure 2.10   Positive MALDI-MS spectra of aqueous γ-CD and 43c 
 
 To better understand the enantiomeric recognition capability of α, β and γ-cyclodextrins 
with guest compounds 43c (Figure 2.5), association constants (Ka, M-1) of 43c with all three 
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cyclodextrins were measured by 1H NMR (500 MHz) at different temperatures. The solution of 
43c (0.001 M) in aqueous NaHCO3 (0.003 M) was titrated with a host cyclodextrin solution. 
Each time the change in chemical shift was measured by NMR spectroscopy. Non-linear 
regression analysis (Figure 2.11) using Origin 6.1 (Aston Scientific Ltd.) generated the 
association constants Ka according to equation (1).264 
 
∆ = ∆maxKa[H]
1 + Ka [H]
Equation (1)
 
 
 Where ∆ = the peak shift in ppm, ∆max = the maximum peak shift in ppm, and [H] = the 
concentration of host. At least two experiments were performed for each system.  
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Figure 2.11   Binding isotherm for the complexation of 43cS and γ-CD at 25 °C 
 
       In Table 2.1, association constants Ka, standard free energy ∆Gº, standard entropy term 
T∆S° and standard enthalpy ∆H° of guest 43c with β and γ cyclodextrin are listed. The chemical 
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shift change of the NMR signal of guest 43c in the presence of α−cyclodextrin was too small to 
measure (as shown in Figure 2.5), and the association constant was considered too small to 
measure practically. Standard free energy was calculated using equation (2). 
      ∆G° = -RT ln Ka      ----------------------- Equation (2) 
 
Standard enthalpy ∆H° was determined according to the Van’t Hoff equation (3). 
    d ln K / d (1 /T) = - ∆H° /R ----------------Equation (3) 
Where R = 8.3144 J K-1mol-1 and ∆H° in J mol-1.  
T∆S° was calculated using equation (4). 
     ∆G° = ∆H° - T∆S°----------------- --------Equation (4)   
 
Table 2.1  1H NMR derived thermodynamic parameters for the binding of guest molecule 43c to 
host β and γ−CD. All K values are in mol-1 unit and ∆Gº, T∆Sº, ∆Hº  values are in kJ/mol  unit.  
 
S-enantiomer R-enantiomer  Temp. 
β-CD γ-CD β-CD γ-CD 
 
298 K      K= 63 ± 20         K = 413 ± 21        K = 47 ± 7      K = 321 ± 20 
  ∆Gº= -10.3 ± 0.7        ∆G º= -14.93 ± 0.13   ∆G º= -9.6 ± 0.3    ∆G º= -14.31 ± 0.15 
  T∆Sº= -4.84 ± 2.9     T∆Sº= -9.70 ± 0.12    T∆Sº= -28.9 ± 1.5  T∆Sº= -18.7 ± 3.5 
 
313 K      K = 43 ± 10       K = 262 ± 12       K = 20 ± 4      K = 211 ± 6 
     ∆G º= -9.2 ± 0.6   ∆Gº= -13.81 ± 0.11 ∆Gº= -7.4 ± 0.4   ∆Gº= -13.26 ± 0.07 
 T∆Sº= -5.7 ± 3.1   T∆Sº= -10.83 ± 0.11   T∆Sº= -31.1 ± 1.6  T∆Sº= -19.7 ± 3.4 
 
343K       K = 27 ± 3       K = 113 ± 5       K = 6 ± 1      K = 59 ± 13 
 ∆Gº= -8.2 ± 0.3   ∆Gº= -11.73 ± 0.11      ∆Gº= -4.5 ± 0.5   ∆Gº= -10.12 ± 0.49 
  T∆Sº= -6.8 ± 3.4      T∆Sº= -12.9 ± 0.1  T∆Sº= -33.9 ± 1.7 T∆Sº= -22.9 ± 3.8 
     
     ∆Hº= -15 ± 3.7 ∆Hº= -24.63 ± 0.01      ∆Hº= -38.4 ± 1.2     ∆Hº= -33 ± 3.4 
 
 As shown in Table 2.1, the association constant of guest 43c is more than seven times 
higher for γ−CD compared to the association constant for β−CD. This is exactly what was 
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predicted from Figure 2.5. The cyclodextrin cavity must be large enough to accommodate two 
aromatic rings. The association constant for S-enantiomer is higher than that of R-enantiomer and 
the association constant (Ka) decreases as temperature increases.   
         In the guest compound 43b (scheme 2.1), the electron rich indole moiety was replaced by 
a phenyl moiety, resulting weaker π-π stacking interaction between aromatic moieties. 
Therefore, as shown in Figure 2.12, α-CD gives no enantiomeric recognition, while β- and γ-CD 
gives a little enantiomeric recognition.  
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Figure 2.12   A portion of NMR spectra of racemic 43b (0.001 M) in aqueous NaHCO3 (0.003 
M) with α, β, and γ-CD (0.01 M), respectively. 
 
 
        Guest compound 43a has only one aromatic ring therefore only γ-CD can give little 
enantiomeric recognition (figure 2.13) while α- and β-CD can not show any enantiomeric 
recognition because neither of these two CD can accommodate the aromatic ring inside their 
cavity. 
43b 
43b in α-CD
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43b in γ-CD
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Figure 2.13  A portion of NMR spectra of racemic 43a (0.001 M) in aqueous NaHCO3 (0.003 
M) with α, β, and γ-CD (0.01 M) respectively. 
 
2.1.3 Isoindole-1,3-Dione Derived Amino Acids 
The π-π stacking interactions between two aromatic moieties strongly depend on the 
magnitude of electron acceptor and electron rich aromatic moiety. The stronger the π-π stacking 
interaction between two aromatic moieties, the better enantiomeric recognition in the racemate 
NMR of the guest compound in the presence of the appropriate host cyclodextrin. Moreover, the 
size of naphthalene ring was responsible for the smaller association constants of guest compound 
43c with α- and β-cyclodextrins. By reduction of acceptor ring size from naphthalene to 
benzene, a series of guest compounds 44a, 44b and 44c have been synthesized and the changes 
in enantiomeric recognition and association constants are studied. 
The synthetic conditions for the preparation of these amino acid derivatives are presented 
in Scheme 2.2.265  Reactions were performed with phthalic anhydride in pyridine with the amino 
acid alanine, phenylalanine and tryptophan (Scheme 2.2).  The isolated yields range between 79-
95%. 
 
30a in β-CD
30a in γ-CD
30a in α-CD
30a  
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Scheme 2.2 Preparation of guest compounds 44a, 44b and 44c 
 
          To observe the formation of self-assembly molecular associates, as demonstrated in Figure 
2.4 for compound 43c, 1H NMR spectra of compound 44c were recorded using different 
enantiomeric compositions of R: S (1:4 and 4:1), as well as using different concentrations, 
ranging from 10-4 to 10-1. In none of the recorded NMR spectra could we detect any resolution of 
enantiomers. One reasonable explanation could be that in both compounds 43c and 44c, the only 
difference is in the size of the electronic acceptor ring. In compound 44c, the naphthalene ring is 
replaced with a benzene ring, which makes it slightly less electron poor, so the LUMO energy of 
this compound would be lower than that of 43c. In the case of 44c, the formed weak self-
assembly molecular associates cannot provide a sufficient different environment for both 
enantiomers to be seen by NMR spectroscopy. 
      Negative electrospray ionization mass spectra (ESIMS) of compound 44cS in alkaline 
aqueous solution was performed in order to detect the formation of a molecular associate. Figure 
2.14 indicates the formation of the molecular dimer with MW 667.1. Failure to observe the NMR 
enantiomer nonequivalence might be due to a weak enantiomer association constant. 
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Figure 2.14  Negative ESIMS of sodium salt of 44c in aqueous solution 
 
       If the association constant for the formation of the self-assembly molecular associate is 
very small due to weak nonbonding π-π stacking interactions of the aromatic moieties, the 
presence of cyclodextrin should stabilize these associates by the binding of the guest molecule 
inside the CD cavity.  In such a case, the NMR spectroscopic recognition could be enforced. This 
is demonstrated in Figure 2.15 for cyclodextrin assisted enantiomeric recognition of racemic 44c. 
The chemical shift change in the racemate NMR in the presence of α-CD indicates a complex 
formation between 44c and outside of the α-CD cavity because the α-CD cavity is not 
sufficiently large enough to form neither the 1:1 nor the other complexes shown in Figure 2.6. 
The best results were obtained in γ-cyclodextrin in comparison with β-cyclodextrin. The β-CD 
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cavity can accommodate either of two aromatic rings of 44c and can form a 1:1 complex but not 
any higher order complexes; therefore, only weak enantiomeric discrimination was observed.  
N
H
CO2H
44c
N
O
O
           
 
 
Figure 2.15  A portion of NMR spectra of 44c (0.001 M) in aqueous NaHCO3 (0.003 M) and 
α, β, γ−CD (0.01 M), respectively  
 
 
   
From the comparison of the racemate NMR with individual enantiomer NMRs in γ-CD, 
the enantiomeric composition and signal assignment can be identified, but more importantly, 
from the proton signal shift it is also possible to deduce which enantiomer will bind more 
strongly with cyclodextrin (Figure 2.16). For example, if the racemate NMR is compared with 
both enantiomer NMRs in the presence of γ-cyclodextrin, there is less influence of γ-CD on 
chemical shift of 44cS. On the other hand, there is a substantial up field chemical shift of indole 
hydrogens (6.8-7.5 ppm) and a downfield shift (7.7 ppm) for phthalimido hydrogens of 44cR in 
the presence of γ-CD. Based on this observation, it might be suggested that γ-CD forms 
preferentially a stronger complex with 44cR compared to 44cS. 
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Figure 2.16 Comparison of γ-CD induced NMR non-equivalency of 44c 
  
Considering that the γ-CD cavity is sufficient enough to accommodate both phthalimido 
and indole moieties, it should form a ternary and higher order complexes with 44c. Since γ-CD 
would form a ternary complex with a 44c dimer, it should not be possible to detect a “free” 44c 
dimer signal at 667.1 m/z (Figure 2.13) in the solution, but rather it should be complexed with 
one γ-CD (981.9 m/z), two γ-CDs (1630 m/z), and three γ-CDs (2278.6 m/z), respectively. This 
is perfectly demonstrated in ESIMS of 44cS (Figure 2.17) with γ-CD.  
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Figure 2.17 ESIMS of 44cS (0.001 M) in DMSO (1 drop) and γ−CD (0.01 M)  
  
         To show the π-π interaction of the electron poor phthalimido moiety hydrogen with the 
electron rich indole moiety hydrogen, which leads to the formation of self-assembly molecular 
aggregates (Figure 2.1), NOESY (Nuclear Overhauser Effect Spectroscopy) NMR spectrum 
(Figure 2.18) of 44cS (0.01 M) in NaHCO3 (0.03 M) was performed on 500 MHz NMR using 
D2O as solvent.  
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Figure 2.18   NOESY NMR spectrum of mixture of 44cS (0.01 M) in aqueous NaHCO3 (0.03 
M) 
 
 
         The π−π stacking interaction between two guest molecules of 44cS is shown in Figure 
2.18.  NOE evidence of π−π stacking interaction between hydrogens of the phthalimido moiety 
(Ha-Hd) and the electron rich indole moiety (He-Hi) are very clear. 
         Formed self-assembly molecular aggregates due to π-π stacking interactions between 
electron rich and electron poor aromatic moieties are very weak. Therefore these aggregates 
stabilize by binding into the cyclodextrin cavity (Figure 2.1). To show the interaction between 
the guest compound 44c hydrogen and host γ-cyclodextrin hydrogen, a NOESY NMR  
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spectrum (Figure 2.19) of mixture of 44cS (0.01 M) and γ-CD (0.01 M) and was performed on a 
500 MHz NMR using D2O as solvent. 
 
 
Figure 2.19   NOESY NMR spectrum of mixture of 44cS (0.01 M) in aqueous NaHCO3 (0.03 
M) and γ-CD (0.01 M)  
 
 
  The interaction between the host γ-cyclodextrin hydrogen and the guest 44cS hydrogen 
(Figure 2.19) can be seen in this NOESY spectrum. For example, all γ-cyclodextrin hydrogens 
(H2-H6) show strong space coupling interactions with guest 44cS hydrogens (Ha-Hd, Hf, He). 
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 To better understand the binding of guest compound 44c with host cyclodextrins, 
association constants (Ka, M-1) were measured by 1H NMR (500 MHz). The solution of 44cS 
(0.001 M) in aqueous NaHCO3 (0.003 M) was titrated with host CD solution at different 
temperatures and after each titration the change in chemical shift was measured.  
 Using equation (1), the binding isotherms for the guest 44cS with 
α−, β− and γ−cyclodextrins were generated to calculate the association constant Ka from which 
the standard free energy was calculated, using the equation (2). 
 
Table 2.2 Association constant Ka and standard free energy ∆G° for the binding of 
guest molecule 44cS to host α, β and γ−CD at 25 °C  
 
Host 
Compd. 
Association 
Const. Ka 
mol-1 
Standard Free Energy 
∆G° 
kJ mol-1 
α-CD 67 ± 13 -10.4 ± 0.5 
β-CD 105 ± 14 -11.5 ± 0.3 
γ-CD 226 ± 13 -13.4 ± 0.2 
 
   As shown in Table 2.2, the association constant of the guest 44cS is highest for γ−CD. 
This is exactly what we predicted from the spectrum indicated in Figure 2.15, and are consistent 
with what we understand from our model Figure 2.1. The cyclodextrin cavity must be large 
enough to accommodate two aromatic rings. It was also found that the association constant for 
the R-enantiomer is higher than that of the S-enantiomer (Table 2.3). It is also interesting to note 
that the association constant of 44cS with α- and β- cyclodextrin is much higher compared to 
guest compound 43cS. As explained earlier, this is due to better fitting of the guest compound 
  56
inside the cyclodextrin cavity. In guest compound 44cS, the naphthalene ring is replaced by a 
smaller phthalimido ring (scheme 2.2). 
 
Table 2.3 Association constant and standard free energy for the binding of guest 
molecule 44cS and 44cR to host γ−CD at 25 °C 
Enantiomer Association Const. 
Ka mol-1 
Standard Free Energy ∆G°   
kJ mol-1 
S 226 ± 13 −13.4 ± 0.2 
R 1050 ± 63 −17.2 ± 0.2 
  
 
 In Table 2.4, the association constant Ka, standard free energy ∆Gº, standard entropy term  
T∆S° and  standard enthalpy ∆H° of the guest 44cS with γ-cyclodextrin at different temperatures 
are listed. As shown in the table, the association constant Ka decreases as the temperature 
increases.  
 
Table 2.4   1H NMR derived thermodynamic parameters for the binding of guest molecule 44cS 
to host γ−CD  
 
Temperature Association Const.  
Ka  Mol-1 
∆Gº 
kJ Mol-1 
∆Hº 
kJ Mol-1 
Τ∆Sº 
kJ Mol-1 
298 K 226 ± 13 -13.4 ± 0.2 -10.9 ± 1.8 
313 K 187 ± 8 -12.9 ± 0.1 -11.4 ± 1.9 
333 K 74 ±  6 -10.7 ± 0.2 
-24.4 ± 2 
-13.7 ± 1.8 
  
 
 To show that for the successful cyclodextrin assistance in the formation of π−π stacking 
molecular complexes, the guest compound must contain both electron-poor and electron-rich 
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aromatic moieties; guest compound 44b and 44a (Scheme 2.2) were synthesized by replacing the 
electron rich indole moiety with phenyl or hydrogen, respectively. By doing so, the π-π 
interaction should be diminished (44b) or removed (44a). As expected, both guest compound’s 
NMR spectra with all three cyclodextrins show no noticeable enantiomeric recognition. 
However, the phthalimido and phenyl ring hydrogen signals in compound 44b and the methyl 
hydrogen signal in compound 44a split into two sets of signals due to perfect fitting of the 
phthalimido ring  into β-CD (Figure 2.20, 2.21). This finding is not surprising considering that 
the cyclodextrin cavity must be large enough to accommodate the ring of the guest compound. 
The α-CD cavity is too small while γ-CD cavity is too big to perfectly accommodate the guest 
compounds.  
     
44b
HO2C
NO O
.  
Figure 2.20 A portion of NMR spectra of 44b (0.001 M) in aqueous NaHCO3 (0.003 M) and 
α, β, γ−CD (0.01 M), respectively. 
 
44b in γ-CD
44b in α-CD
44b
44b in β-CD
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44a
HO2C CH3
NO O
.  
 
Figure 2.21   A portion of NMR spectra of 44a (0.001 M) in aqueous NaHCO3 (0.003 M) and 
α, β, γ−CD (0.01 M), respectively. 
  
 
       Association constants (Ka) for guest compound 44aS with all three cyclodextrins are listed 
in Table 2.5. As explained earlier, guest compound 44aS shows better enantiomeric recognition 
with β-CD (Figure 2.21), and the association constant with β -CD is higher than that with α- and 
γ-CD. 
Table 2.5  Association constant and standard free energy ∆G° for the binding of 
guest molecule 44aS to host α, β and γ−CD 
  
Host Compd. Association 
Const. Ka 
mol-1 
Standard Free 
Energy ∆Gº 
kJ mol-1 
α-CD 64 ± 10 -10.3 ± 0.4 
β-CD 227 ± 17 -13.5 ± 0.2 
γ-CD 82 ± 6 -10.9 ± 0.2 
 
         The association constant (Ka) is different for both enantiomers of the racemate. It was also 
found that the association constant for 44aR is higher than that of 44aS with γ-CD (Table 2.6).  
44a in α-CD 
44a in β-CD 
44a in γ-CD 
44a 
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Table 2.6 Association constant and standard free energy ∆G° for the binding of guest 
molecule 44aS and 44aR to host γ−CD at 25 °C  
 
Enantiomer Association Const. Ka 
mol-1 
Standard Free Energy ∆G°   
kJ mol-1 
S 82 ± 6 -10.9  ± 0.2 
R 141 ± 30 -12.3 ±  0.6 
 
 
2.1.4 Hexahydro-isoindole-1,3-dione derived amino acids 
To show that the electron acceptor aromatic moiety is also very important for π−π 
stacking molecular complex formation between host cyclodextrin and guest compounds, we 
synthesized guest compounds 45a, 45b and 45c (Scheme 2.3), and studied their binding 
capability with different cyclodextrins. None of these series of guest compounds have electron 
acceptor aromatic moieties. 
The synthetic conditions for the preparation of these amino acid derivatives are presented 
in Scheme 2.3.  Reactions were performed with 1,2-cyclohexanedicarboxylic anhydride in 
pyridine with the amino acids alanine, phenylalanine and tryptophan (Scheme 2.3).  The isolated 
yields range between 90-93 %. 
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Scheme 2.3 Preparation of guest compounds 45a, 45b and 45c. 
  
 
 1H NMR spectroscopic study of the guest compounds 45a, 45b and 45c with all three 
α, β, and γ CD does not show significant enantiomeric recognition. This was expected 
considering that for strong π−π stacking interactions the guest compound should have both an 
electron acceptor and an electron donor aromatic moiety.  
            The 1H NMR spectra of guest compound 45c shows a slight shift of proton signals in the 
presence of α, β, and γ−CD. In the presence of β-CD, there is slight enantiomeric recognition 
(Figure 2.22). The two triplets of the indole ring split into two sets of triplets that are slightly 
overlapped. We believe that this observed enantiomeric spectroscopic non-equivalence might 
come from only the 1:1 cyclodextrin complex with indole moiety in β-CD. 
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 Figure 2.22 A portion of NMR spectra of 45c (0.001 M) in aqueous NaHCO3 (0.003 M) and 
α, β, γ−CD (0.01 M), respectively. 
 
      The 1H NMR spectra of guest compound 45b shows a slight shift of proton signals in the 
presence of α−, β− and γ−CD, but no significant enantiomeric recognition (Figure 2.22). 
 
45b
HO2C
NO O
.                                 
Phenyl ring Hydrogen 
 
Figure 2.23 A portion of NMR spectra of 45b (0.001 M) in aqueous NaHCO3 (0.003 M) and 
α, β, γ−CD (0.01 M) 
45b 
45b in α-CD 
45b in β-CD 
45b in γ-CD 
45c in α-CD
45c in β-CD
45c in γ-CD 
45c 
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      The 1H NMR spectra of racemate 45a in the presence of α−, β− and γ−CD are shown in 
Figure 2.24. Compound 45a has no aromatic moiety. The racemate NMR of 45a in the presence 
of β-CD shows diminutive enantiomeric recognition. Two quartets, each from different 
enantiomers are slightly shifted, giving an impression of a pentet. The methyl hydrogen gives 
two sets of doublets. Signals from both enantiomers are shifted more with β-CD compared to γ-
CD. Thus, β-CD gives slightly better enantiomeric recognition compared to γ-CD. 
 
45a
HO2C CH3
NO O
.  
   H attached to chiral carbon                    Methyl Hydrogen 
Figure 2.24 A portion of NMR spectra of 45a (0.001 M) in aqueous NaHCO3 (0.003 M) and 
α, β, γ−CD (0.01 M) 
 
 
2.1.5 Succinamic Acid Derived Amino Acids 
         To show that the presence of the electron-poor aromatic moiety is crucial for the formation 
of the molecular assemblies discussed in Figure 2.1, mono amino acid amides with succinic acid 
were prepared (Scheme 2.4). The reaction progress was optimized and monitored by NMR 
45a 
45a in α-CD 
45a in β-CD 
45a in γ-CD 
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spectroscopic studies.  After all reaction conditions were optimized, the isolated yields of the 
target compounds were between 83-96 %. 
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Scheme 2.4 Preparation of guest compounds 46a, 46b, and 46c 
 
         These compounds, 46a, 46b, and 46c, are very soluble in water.  Spectroscopic studies of 
racemic and non-racemic solutions of these guest compounds at higher concentrations and 
different enantiomeric ratios were studied in DMSO and water. We did not observe NMR non-
equivalency of enantiomers for any of these compounds. Even the racemate NMR of 46a, 46b, 
and 46c in the presence of α-, β- and γ-cyclodextrin did not show enantiomeric recognition 
either. However, we were able to detect the formation of CD complexes with guest compounds 
46b and 46c through ESIMS studies.  From this finding it is obvious that these cyclodextrin 
complexes cannot produce a different NMR environment to observe enantiomeric recognition 
through NMR spectroscopy. As shown in Figures 2.25, 2.26 and 2.27, none of these guest 
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compounds shows enantiomeric recognition in the presence of α−, β− and  γ−CD. Only a slight 
change in the NMR signal can be seen, which indicates the formation of inclusion complexes.  
46c
N
OH
O
OH
HO2C
N H
.  
Figure 2.25 A portion of NMR spectra of 46c (0.001 M) in α, β, γ−CD (0.01 M) 
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Figure 2.26 A portion of NMR spectra of 46b (0.001 M) in α, β, γ−CD (0.01 M) 
 
 
 
46b  
46b in α-CD 
46b in γ-CD 
46b in β-CD 
46c in α-CD
46c in β-CD
46c in γ-CD
46c 
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Figure 2.27 A portion of NMR spectra of 46a (0.001 M) α, β, γ−CD (0.01 M) 
 
 
           Association constants (Ka) of guest compound 46cS with all three cyclodextrins are listed 
in Table 2.6. Compound 46cS has a higher association constant with γ-CD compared to α− and 
β-CD. This is probably due to better fitting of the indole moiety inside γ-CD cavity.   
 
Table 2.7   Association constant and standard free energy ∆G° for the binding of 
guest molecule 46cS to host α, β and γ−CD 
  
Host Compd. Association 
Const. Ka 
mol-1 
Standard Free 
Energy ∆Gº 
kJ mol-1 
α-CD 56 ± 10 -9.9 ± 0.7 
β-CD 81 ± 9 -10.9 ± 0.3 
γ-CD 188 ± 17 -12.9 ± 0.2 
 
 
 
46a in α-CD
46a 
46a in γ-CD
46a in β-CD
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2.1.6 Amino-(1H-indol-3-yl)-Acetic Acid Derived Guest Compounds 
        Guest compounds 43c, 44c, 45c, and 46c have been synthesized using different electron 
acceptor moieties and tryptophan as the electron donor aromatic moiety. In tryptophan, there is a 
–CH2 group that connects the chiral carbon with the indole ring, which makes the indole ring 
very flexible, resulting in poor interaction with the host cyclodextrin during complex formation. 
Inoue and coworkers, during their study of complexation ability of different guest compounds 
with cyclodextrins, proposed that the change in the length of tether which connects two aromatic 
moieties of guest compounds can dramatically change the ability of the aromatic rings to adjust 
their position within CD cavity and thus enantiomeric recognition property.266  To check this, we 
have planned to synthesize derivatives of the guest compounds 43c, 44c, 45c, and 46c by 
replacing tryptophan with amino-(1H-indol-3-yl)-acetic acid (52) (Scheme 2.5). The new guest 
compounds with amino acid 52 as the electron rich moiety will be more rigid and should form 
more stable diastereomeric inclusion complexes with cyclodextrins. The synthetic strategy for 
the synthesis of amino acid 52 is outlined in Scheme 2.5.  
HN
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Scheme 2.5 Synthetic strategy for synthesis of 52 
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       Our initial synthetic preparations include the following results:  Transimination of the 
reactive benzophenone equivalent, benzophenone imine 47 with the amino ester salt, glycine 
ethyl ester hydrochloride 48 in dichloromethane at room temperature for 24 hour gave 49 in 94% 
yield.267 The stable electrophilic glycine synthon 50 was prepared directly from the Schiff base 
49 by bromination in the presence of sodium acetate in 70% yield.268 Attempts to convert the 
electrophilic glycine cation equivalent 50 into 51 using TiCl4 as a Lewis acid and indole as a 
nucleophile were not successful. 
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2.2 Amino Acid Imide Guest Compounds with Two Chiral Centers 
 
2.2.1 Cyclodextrin Assisted Formation of Homochiral Polymer-Like Associate in Two 
Chirality System 
 
        Cyclodextrins can also form diasteromeric inclusion complexes with racemates that have 
two chiral centers, one relatively large aromatic acceptor, and two smaller electron-rich aromatic 
moieties.  A graphical representation of proposed guest compound is shown in Figure 2.28.  
Considering structural properties, molecule M should also form molecular self-assembly as 
described earlier in figure 2.1.259  
 
do
no
r
MOOC do
no
r
COO
acceptor
 
Figure 2.28 Chiral molecule with two donors and one acceptor 
 
        Since compound M has both electron-deficient and electron-rich aromatic moieties, it 
should form molecular associates through dimerization, trimerization, etc. by nonbonding 
aromatic interactions.  The stability of molecular associates can be enhanced by binding into the 
cyclodextrin cavity and forming inclusion complexes (Figure 2.29). 
do
no
r
O2C do
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CO2
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Figure 2.29 Possible molecular associates in aqueous cyclodextrin solutions 
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2.2.2 Benzo[lmn][3,8]Phenanthroline Derived Amino Acids 
         Three amino acids were chosen from which guest compounds 53a, 53b and 53c were 
prepared for the study of the formation of molecular aggregates (Scheme 2.26).269    The central 
aromatic portion of the guest compounds 53a, 53b and 53c is electron-deficient containing a 
naphthalene ring with four carbonyl groups. The two indole moieties of tryptophan in 53c and 
phenyl moiety of phenylalanine in 53b make these parts of these compounds electron rich. 
Aromatic π-π interactions in compounds 53c and 53b make it possible to form self-assembly 
molecular associates. The formation of these associates is not possible for compound 53a, which 
does not contain an additional aromatic moiety, but was synthesized to demonstrate the necessity 
of second aromatic moiety (Scheme 2.6). Isolated yields are between 90-97%. 
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Scheme 2.6 Synthetic transformations of three amino acids into 53a, 53b, and 53c 
 Electro-spray mass spectroscopic studies of three cyclodextrins, α−, β− and 
γ−cyclodextrins with guest compounds 53a, 53b and 53c were carried out to study the formation 
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of molecular associates. In aqueous solution, the guest molecules 53a, 53b and 53c can form 
molecular aggregation by dimer, trimer, etc. For example, negative ESIMS of 53a in methanol-
water solution shows a molecular peak at 819.3 corresponding to dimer (2M) of 53a (Figure 
2.30).  This finding indicates the formation of molecular self- assembly of 53a, 53b, and 53c in 
solution.  
 
 
Figure 2.30 Negative ESIMS of 53aS in methanol-water 
 
   In the ESIMS spectra of all three guest compounds 53a, 53b and 53c, molecular 
aggregates in aqueous media were observed with and without cyclodextrins.  This was 
demonstrated with the negative ESIMS of 53a in aqueous α-cyclodextrin (Figure 2.31).  The 
signal intensity of the molecular dimer (2M-H+=818.8 m/z) of 53a increased with reference to 
the molecular signal (M-H+=409 m/z) (Figure 2.29).  Formation of the molecular trimer (3M-
H+=1229 m/z) was also observed.  Complex formation with α-cyclodextrin (1:1) was also 
observed (1381.7 m/z), but higher order complex formation was not observed. Since compound 
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53a does not have an electronic rich moiety present, it cannot form self-assembly molecular 
aggregates through aromatic stacking interactions, only through hydrogen bonding interactions 
present in two carboxylic acid groups. 
 
Figure 2.31 Negative ESIMS of 53aS in aqueous α-cyclodextrin solution 
 
  Since molecule 53c contains both electron rich and electron poor aromatic moieties, it is 
capable of forming molecular associates through aromatic stacking interactions, and γ-
cyclodextrin (largest cavity size) might stabilize these molecular associates by forming inclusion 
complexes with the aggregates. Negative ESIMS spectra indicates the formation of self-assembly 
molecular dimers (2M, 1279.4 m/z) as well as formation of molecular complexes with 
cyclodextrin that are of higher order than 1:1, such as a 2:1 (2M+1γCD) and 1:2 (1M+2γCD) 
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(Figure 2.32).  This suggests that due to the formation of high order diastereomeric molecular 
complexes, spectroscopic enantiomeric discrimination of 53c should occur.  
 
 
Figure 2.32 Negative ESIMS of 53cS (0.001 M) in DMSO (1drop) and γ-cyclodextrin (γ−CD, 
0.001 M). 
 
         The ESIMS is very good in demonstrating the formation of molecular complexes through 
molecular peaks, but to study the enantiomeric recognition or discrimination capability of 
cyclodextrins with  guest compounds 53a, 53b and 53c,  the NMR spectroscopic studies were 
performed. 1H spectra of racemic 53a, 53b and 53c were recorded in aqueous cyclodextrin 
solutions.   
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Figure 2.33 A portion of NMR spectra of 53a (0.001 M) in aqueous NaHCO3 (0.003 M) and 
α, β, γ-CD (0.01 M). 
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Figure 2.34 A portion of NMR spectra of 53b (0.001 M) in aqueous NaHCO3 (0.003 M) and 
α, β, γ-CD (0.01 M) 
 
  
         NMR discrimination of alkaline aqueous solutions of racemic 53a (Figure 2.33) was not 
observed in the presence of α-, β- and γ-cyclodextrin. There is little enantiomeric recognition of 
53b
53b in α-CD
53b in γ-CD
53b in β-CD
53a
53a in α-CD
53a in β-CD
53a in γ-CD
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compound 53b (Figure 2.34) seen with β-CD. This is surprising, considering that the ESIMS 
spectra of 53a and α-cyclodextrin (Figure 2.31) clearly show the formation of molecular 
complexes. The reasonable explanation could be that these molecular complexes are not 
inclusion complexes but rather formed by hydrogen bonding interactions on the outside of the 
cyclodextrin cavity. What we see in the NMR spectrum is the average association of a molecule 
that is in fast equilibrium with many different aggregates.  For better enantiomeric recognition it 
is important that guest molecules 53a, 53b and 53c form strong diastereomeric complexes with 
cyclodextrin as the molecular dimer.  For instance, the formation of a ternary complex between 
53a in α-cyclodextrin is not evident in the ESIMS spectra (Figure 2.31). Contrary to this, there is 
a strong signal for the ternary β-cyclodextrin complex with the 53cS dimer (Figure 2.35). 
 
Figure 2.35 Negative ESIMS spectra of 53cS in aqueous β-cyclodextrin 
        This is demonstrated in the 1HNMR spectroscopic study of the enantiomeric 
discrimination of 53c in aqueous cyclodextrins (Figure 2.36). The racemic mixture of 53c in 
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water shows only one set of signals for both enantiomers. Enantiomeric recognition is not 
observed in the presence of α-CD considering that the guest molecule 53c is too big to enter the 
α-cyclodextrin cavity and a diastereomeric inclusion complex cannot be formed (Figure 2.36). 
The cavity of β-cyclodextrin can accommodate the molecular size of 53c; therefore, 
diastereomeric inclusion complexes are formed and NMR recognition is observed (Figure 2.36).  
Considering the large cavity size of γ-cyclodextrin, it can form a ternary inclusion complex (2M+ 
γ-CD, 1616.6 m/z in Figure 2.32). Formation of a strong ternary complex resulted in its lower 
water solubility and difficulty in NMR characterization (Figure 2.36).      
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Figure 2.36 A portion of NMR spectra of 53c (0.001 M) in aqueous NaHCO3 (0.003 M) and 
α, β, γ-CD (0.01 M), respectively 
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2.2.3 Pyrrolo[3,4-f]Isoindole Derived Amino Acids 
        To study the formation of molecular aggregates (Figure 2.29); another series of guest 
molecules were synthesized by replacing the naphthalene ring of the central portion with a 
smaller benzene ring. By doing so, the newly synthesized guest compounds 54a, 54b and 54c 
now have smaller electron acceptor aromatic moieties in comparison  to 53a, 53b and 53c.  
The synthetic conditions for the preparation of these amino acid derivatives are presented 
in Scheme 2.7.  Reactions were performed with 1,2,4,5-benzenetetracarboxylic dianhydride in 
pyridine with the amino acids alanine, phenylalanine and tryptophan.  The isolated yields of the 
target compounds range between 81-90 %. 
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Scheme 2.7 Preparation of guest compounds 54a, 54b and 54c 
 
 
        NMR spectroscopic studies of the cyclodextrin aqueous solution of racemic 54a, 54b and 
54c were performed with the intent to study the enantiomeric recognition ability of these guest 
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compounds. Guest compounds 54a (Figure 2.37) and 54b (Figure 2.38) in the presence of β-CD 
show little enantiomeric recognition by NMR spectroscopy.  
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Figure 2.37 A portion of NMR spectra of 54a (0.001 M) in aqueous NaHCO3 (0.003 M) and 
α, β, γ-CD (0.01 M), respectively 
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Figure 2.38 A portion of NMR spectra of 54b (0.001 M) in aqueous NaHCO3 (0.003 M)  
and α, β, γ-CD (0.01 M), respectively 
 
 
     The NMR spectra of 54c in α−, β− and γ−CD are presented in Figure 2.39. Τhe 
cyclodextrin cavity must be large enough to accommodate two aromatic rings. In α-cyclodextrin, 
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  78
no NMR spectroscopic recognition was observed due to the fact that neither the indole nor the 
1,2,4,5-benzenetetracarboxylic dianhydride aromatic moieties can bind into the α-cyclodextrin 
cavity. The β-cyclodextrin cavity is large enough to accommodate part of the molecule, 
therefore, slight enantiomeric discrimination is observed in the racemate NMR of 54c in β-CD. 
Guest molecule 54c forms molecular aggregates through aromatic stacking interactions and this 
aggregate binds into the cyclodextrin cavity, forming strong diastereomeric complexes. The 
lower solubility of these complexes in water makes it difficult to characterize the NMR spectra 
(Figure 2.39).  
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Figure 2.39 A portion of NMR spectra of 54c (0.001 M) in aqueous NaHCO3 (0.003 M) and 
α,β,γ−CD (0.01 M), respectively 
 
 
Due to lower solubility of the γ-CD assisted inclusion complexes of 54c in water, we 
found it difficult to observe enantiomeric resolution in NMR spectroscopy, but negative ESIMS 
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of 54cS (Figure 2.40) with γ-CD shows the complex formation of 1:1, 2:1 and 3:1 γ-CD 
complexes with 54cS (signals at 942.74, 1590.88 and 2239.59, respectively).  All other 
molecular complexes are present as well.  
 
 
Figure 2.40 Negative ESIMS of 54cS (0.001 M) in DMSO (1drop) and γ-cyclodextrin (γ−CD, 
10-2 M) 
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III. Toward Synthesis of Dolabellane Diterpenoid B 
 
 3.1 Retro-Synthetic Scheme of Dolabellane Diterpenoid B 
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         Among the four dolabellane diterpenoids isolated from the Okinawan soft coral of the 
genus Clavularia by Iguchi and co-workers (Figure 1.10),225 the dolabellane diterpenoid B is 
unique in that it has an absence of a ketone moiety on carbon 13, which makes it very difficult to 
synthesize this diterpenoid. Conversion of dolabellane diterpenoid C into B by reduction of the 
ketone moiety on C-13 using general reduction methods such as Clemmensen reduction, Wolff-
Kishner reduction or other methods cannot be applied because the epoxide moiety cannot survive 
the harsh conditions associated with these types of reductions. Since there is no synthetic study 
of compound B, we have decided to carry out the total synthesis of compound B and produce 
enough material to further explore the biological properties (antibacterial, antimicrobial, and 
antitumor activities) of this diterpeniod.233, 196-198 
        The retro-synthetic scheme of dolabellane diterpenoid B is outlined in Figure 3.1. 
Convergent synthetic approach is applied by synthesizing Fragment 1 and Fragment 2 
individually, and then conducts the final ring closing step in a reaction between these two 
fragments.  
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Figure 3.1 Retro-synthetic schemes for diterpenoid B 
 
3.2 Proposed Synthetic Strategy for Target Molecule B 
        Our synthetic approach to Fragment 1 was selected due to the fact that this compound could 
be prepared from 2-methyl-1,3-butadine (55) by following previously reported synthetic 
procedures.  The first step involves acetoxychlorination270-272 of the diene 55 using procedure a, 
b or c (Scheme 3.1). The acetate intermediate 56 could be hydrolyzed and tosylated to afford 
Fragment 1 (Scheme 3.1). 
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Cl
OTs
Cl
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Fragment 155 56
Na2CO3, H2O
TsCl
(a) Benzoquinone, AcOH, LiCl, LiOAc, Pd(OAc)2
(b) t-Butylhypochlorite, AcOH
(c) NCS, AcOH
(a), (b) or (c)
 
Scheme 3.1 Literature preparation scheme for Fragment 1. 
 
       Considering that the literature procedure for the preparation of Fragment 1 is available, 
major attention was focused on developing a reliable synthetic procedure for the preparation of 
Fragment 2 and then its coupling to Fragment 1 to produce diterpenoid B.  Based on our 
literature search, the proposed reaction sequence and the reaction conditions are presented in 
Scheme 3.2. 
  83
O
H
O
H
MsO
PhO2S
H
Cl
TBDMSO
THPO
MeO2C H(4) CH3MgBr, CuI
THPO
TsO
H
(3) NaOCH3, PhSH
(2) LiHMDS, ClCO2Me
THPO
TBDMSO
H
(3) Me2AlCl 
(4) MgI2
HO
HO
H
O
O
(1)TBDMSCl  
(2)dihydropyran, PPTS
Ph3P C
O O
O
MgBr
O OO
B
(1) KHMDS
(2) Na-Hg , Na2HPO4
(2) MsCl
Fragment 2
(1) DIBAH
(1) nBu4NF
(2) TsCl(3) Me3SiI
(4)
(2) 9-BBN, H2O2,OH
-
(1)(1) H2O2
(2)
57 58 59
60 61
62
63 64
65
(2) TBDMSCl
(1) LiCCH
I
HTBDMSO
(1) n-BuLi
(2) Fragment 1
(2) TBAF
(3) PhSSPh, n-Bu3P
(4) oxone
(1) Ti(OiPr)4, (-) DET,
H
HO
PhO2S
(1) NMP, H2O
t-BuOOH
 
Scheme 3.2 Proposed synthetic scheme and reaction conditions for the preparation of Fragment 
2 and its coupling to Fragment 1.        
 
3.3 Accomplished synthesis toward Target Molecule B 
          The first step in the realization of synthetic Scheme 3.2 is the preparation of epoxyketal 
58 (Scheme 3.2). Commercially available expensive starting material 3-methyl-2-cyclopentenone 
57 can be prepared very easily from the comparably inexpensive starting material acetonyl 
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acetone 56a via a base-induced intramolecular aldol reaction (Scheme 3.3).274 Refluxing 56a 
with NaOH in toluene followed by distillation under reduced pressure gave pure product 57. The 
double bond of 57 was epoxidized273 in high isolated yield using H2O2 in the presence of a 
freshly prepared alloy catalyst HT(MO)273 (Mg9.5Al2.6(OH)24.8CO3.nH2O) (Scheme 3.3).   
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Scheme 3.3 Epoxidation-ketalization approach 
 
          Unfortunately, we were not successful in protecting the keto group of 57a without 
epoxide ring opening.  Therefore, we designed a new synthetic route for the conversion of 57 
into 58 (Scheme 3.4). A literature search showed that direct ketalization of α−β unsaturated 
ketones is very difficult. So epoxyketal 58 was synthesized using an indirect route.275  To make 
ketalization more efficient, the double bond was protected by the addition of p-tolunesulfinic 
acid which gave Michael product 57b. Now ketone 57b could easily be protected by refluxing 
with 2,2-dimethyl-1,3-dioxolane276 (1,2-ethanediol equivalent) and a trace amount of p-
toluenesulfonic acid in benzene.  The double bond was regenerated by elimination of the p-
tolunesulfinic acid group of 57c using a strong base, n-butylithium. The α−β unsaturated ketal 
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57d was oxidized277,278 into an epoxide in two steps: (i) the addition of HOBr to the double bond 
using NBS as a source of positive bromine and DMSO as solvent gave 45e (ii)  the bromohydrin 
adduct 57e was converted to epoxide 58 by ring closing using NaH in anhydrous THF (Scheme 
3.4). 
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NaH/THF
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Scheme 3.4 Multi-step preparation of epoxyketal 58 
 
         The next step of our proposed synthetic route (Scheme 3.2) is the transformation of 
epoxyketal 58 into dialcohol 59 by selective epoxide ring opening with vinylmagnesium 
bromide.  Unfortunately, neither vinylmagnisium bromide nor lithium acetylide produced 
satisfactory products of epoxide ring opening (Scheme 3.5).  Through a study of the product 
distribution of these two reactions, it was obvious that the presence of the ketal group hampered 
the nucleophilic addition to the epoxide ring.  Again a new synthetic route was developed to 
bypass this synthetic intermediate. 
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Scheme 3.5 Nucleophilic epoxide ring opening of 58 
 
           In our new approach, instead of ketalizing, we planned to olefinate the keto group of 57a 
using a Wittig reagent (Scheme 3.6). Nucleophilic epoxide ring opening can now be 
accomplished with vinylmagnesium bromide to generate the desired alcohol 58e, which would 
later be converted into fragment 2 after accomplishing a few more steps as described in scheme 
3.2.   
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Scheme 3.6 Proposed synthetic approach for the preparation of 58e 
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IV. Conclusions 
 
          We have shown spectroscopic evidence for the formation of cyclodextrin assisted 
molecular aggregates with chiral amino acid imides. If the amino acid guest compounds contain 
both electronic rich and electronic poor aromatic moieties, strong π−π stacking interactions 
between these aromatic moieties are responsible for the formation of molecular associates that 
bind into the cyclodextrin cavity. This results in spectroscopic enantiomeric discrimination. The 
cyclodextrin cavity must be large enough to accommodate the two aromatic rings. Cyclodextrins 
with smaller cavities show little or no enantiomeric recognition. In the absence of any of these 
aromatic moieties (electronic rich or electronic poor), the polymer-like molecular aggregate 
cannot be formed or is only weakly formed. In amino acids containing no aromatic moiety or 
only an electron deficient aromatic moiety, the aggregate formation occurs through carboxylic 
hydrogen-bonding interactions, which is not sufficient to produce a different NMR environment 
needed to cause the NMR spectroscopic recognition.  
 
The unique structure of dolabellane diterpenoid B makes its synthesis difficult. Some of the 
methods used for the construction of general trans-bicyclo[9.3.0]tetradecane ring structure 
cannot be used in the synthesis of dolabellane diterpenoid B. During the synthesis of dolabellane 
diterpenoid B, the first epoxydation-ketalization approach was unsuccessful because of the 
sensitive epoxide ring functionality. In the second indirect approach, the presence of the ketal 
moiety hampered the nucleophilic epoxide ring opening of the epoxyketal intermediate. A new 
synthetic approach has been designed to overcome these problems toward the synthesis of 
dolabellane diterpenoid B.   
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V. Experimental Section 
 
5.1 General 
 Melting points were taken on an Electrothermal IA 9000 Digital Melting Point Apparatus 
and are uncorrected.  The 1H and 13C NMR spectra were run on Varian Unity 300, 400 and 
Varian INOVA 500 MHz spectrophotometer with CDCl3, D2O or DMSO-d6 as a solvent. The 
mass spectra were recorded on a Micromass Quattro 2 Triple Quadropole Mass Spectrometer; 
Optical rotations of guest compounds were detected at 25°C with the light of sodium D-line (589 
nm) using Autopo III automatic polarimeter Rudolph Research, Flanders, New Jersey. Elemental 
Analysis was performed by Atlantic Microlab, Inc., Norcross, GA. NOESY spectra were 
recorded on 500 MHz spectrophotometer using D2O as a solvent and mixing time was kept 0.3 
sec. 
 
5.2 Synthesized Compounds 
 Preparation of (S)-2-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)propionic acid 
(43aS).  Dimethyl sulfoxide (30 mL) solution of benzo[de]isochromene-1,3-dione (1.98 g; 0.01 
mol) and alanine (0.89 g; 0.01 mol) was refluxed for 1 h.  Reaction mixture was cooled to room 
temperature and slowly added into stirring water (200 mL).  Formed precipitate was separated by 
filtration, washed with water (3x30 mL) and dried at 110 °C for a few hours to afford 2.15 g 
(80%) pure product. mp 257-261 ºC. 1H NMR (DMSO-d6, 500 MHz): δ ppm:  8.51 (dd, 4H, J1  
10.5 Hz ; J2  7.5Hz), 7.89 (t, 2H, J=7.5Hz), 5.54 (q, 1H, J  7 Hz), and 1.53 (d, 3H, J  6.5 Hz).  
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13C NMR (DMSO-d6, 500 MHz) δ ppm:   171.4, 162.9 (carbonyls), 134.7, 131.3, 131.1, 127.4, 
121.7 (aromatic carbons), 48.5(chiral carbon CH), 14.5 (methylene carbon).  MS-ES+ (CH3OH) 
m/z 292.2 (65%, M+Na+), 324.1 (85%, M+CH3OH+Na+), 561.3 (100%, 2M+Na+), and 829.8 
(50%, 3M+Na+).  Anal. Calcd for C15H11NO4 (269.07): C, 66.91; H, 4.12; N, 5.20 Found: C, 
66.85; H, 4.21; N, 5.11. 
 Preparation of (R)-2-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)propionic acid 
(43aR).  The stereoisomer R was prepared in 87% yield by following procedure for preparation 
of S isomer. mp 258-261 ºC. 1H NMR (DMSO-d6, 300 MHz): δ ppm:  8.50 (dd, 4H), 7.89 (t, 2H, 
J=7.5Hz), 5.57 (q, 1H, J 6.9 Hz), and 1.52 (d, 3H, J 6.6 Hz).  13C NMR (DMSO-d6, 500 MHz) δ 
ppm:   171.5, 162.9 (carbonyls), 134.7, 131.3, 131.1, 127.3, 121.7 (aromatic carbons), 48.5(chiral 
carbon CH), 14.5 (methylene carbon). 
 Preparation of (S)-2-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-3-phenyl-propionic 
acid (43bS).  Pyridine solution (150 mL) of benzo[de]isochromene-1,3-dione (0.99 g; 5 mmol) 
and L-phenylalanine (0.825 g; 5 mmol) was refluxed for 6 h.  Volume of the reaction mixture 
was reduced to ~ 5 mL and hot reaction mixture was added to ice cooled aqueous hydrochloric 
acid (150 mL water and 50 concd. HCl).  Formed solid precipitate was separated by filtration, 
washed with water (3x20 mL) and dried at 110 °C for a few hours to afford 1.6 g (93%) pure 
product. mp 250-252 ºC  1H NMR (DMSO-d6, 500 MHz) δ ppm:  8.41 (d, 2H naphthalene ring , 
J=7 Hz), 8.37 (d, 2H naphthalene ring , J 7 Hz), 7.78 (t, 2H naphthalene ring, J  7.5 Hz,), 7.14 (d, 
2H, J 7.5 Hz), 7.07 (2H, t, J 7.5Hz) 7.00 (t, 1H, J 7.5 Hz) 5.92 (dd, 1H, J1  10 Hz ; J2  5.5 Hz) 
3.58 (dd, 1H, J1  14 Hz ; J2  5.5 Hz), and 3.39(dd, 1H, J1  14.5 Hz ; J2  10 Hz).  13C NMR 
(DMSO-d6, 500 MHz) δ ppm: 170.9, 163.0 (carbonyls), 137.9, 134.7, 131.2, 129.0, 128.1, 127.5, 
127.3, 127.2, 126.3, 121.2 (10 aromatic carbons), 53.9 (chiral carbon CH), and 34.3 (methylene 
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carbon). MS-ES- m/z 344 (100% M-H+). Anal. Calcd for C21H15NO4 (345.10): C, 70.03; H, 4.38; 
N, 4.06. Found: C, 69.91; H, 4.42; N, 3.95. 
 Preparation of (R)-2-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-3-phenyl-propionic 
acid (43bR).  Stereoisomer R was prepared in 91% yield and has same spectroscopic 
characteristics as stereoisomer S. mp 250-252 ºC  1H NMR (DMSO-d6, 500 MHz) δ ppm:  8.39 
(d, 2H naphthalene ring , J=7 Hz), 8.29 (d, 2H naphthalene ring , J 7 Hz), 7.73 (t, 2H 
naphthalene ring, J  8 Hz,), 7.16 (d, 2H, J 7.5 Hz), 7.07 (2H, t, J 7Hz) 7.00 (t, 1H, J 7 Hz) 5.97 
(dd, 1H, J1  10 Hz ; J2  5.5 Hz) 3.61 (dd, 1H, J1  12.5 Hz ; J2  5.5 Hz), and 3.39(dd, 1H, J1  13.5 
Hz ; J2  10.5 Hz).  13C NMR (DMSO-d6, 500 MHz) δ ppm: 170.8, 163.0 (carbonyls), 137.9, 
134.7, 131.2, 129.0, 128.1, 127.5, 127.3, 127.2, 126.3, 121.2 (10 aromatic carbons), 53.9 (chiral 
carbon CH), and 34.3 (methylene carbon). 
 Preparation of (S)-2-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-3-(1H-indol-3-yl)-
propionic acid (43cS).  Dimethyl sulfoxide (30 mL) solution of benzo[de]isochromene-1,3-
dione (0.99 g; 5 mmol) and L-tryptophan (1.04 g; 5 mmol) was heated at 150 ºC for 30 min.  Red 
colored reaction mixture was slowly added into stirring water (200 mL).  Formed yellow 
precipitate was separated by filtration, washed with water (3x20 mL) and dried at 110 °C to give 
1.6 g (83%) of pure product. mp 235-239 ºC.  1H NMR (DMSO-d6, 400 MHz) δ ppm: 12.80 (br 
s, 1H), 10.63 (1H, s), 8.44 (dd, 4H, J1 4.4 Hz, J2 7.2 Hz), 7.85 (t, 2H, J 7.6 Hz), 7.46 (d, 1H, J 8.0 
Hz), 7.17 (d, 1H, J 7.6 Hz), 6.99 (s, 1H,), 6.92 (t,1H, J 7.6 Hz), 6.79 (t,1H, J 7.2 Hz), 5.88 (dd, 
1H, J1 9.6 Hz, J2 5.6 Hz), 3.65 (dd, 1H, J1 14.8 Hz, J2 5.6 Hz), 5.54 (dd, 1H, J1 14.8 Hz, J2 9.6 
Hz),13C NMR (DMSO-d6, 500 MHz) δ ppm: 171.0, 163.1, 135.9, 134.7, 131.2, 127.4, 127.2, 
123.5, 121.4, 120.8, 118.2, 118.0, 111.3, 110.3, 53.7, and 24.0 ppm. ESI+ (CH3CO2H) m/z 385 
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(100, M+H+) and 769 (45%, 2M+H+). Anal. Calcd for C23H16N2O4 (384.38): C, 71.87; H, 4.20; 
N, 7.29 Found: C, 71.55; H, 4.31; N, 7.18. 
 Preparation of (R)-2-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-3-(1H-indol-3-yl)-
propionic acid (43cR).  The R stereoisomer has same spectroscopic characteristics as S isomer 
and is prepared in 87% isolated yield by following the S preparation procedure. mp 235-238 ºC. 
1H NMR (DMSO-d6, 400 MHz) δ ppm: 12.80 (br s, 1H), 10.64 (1H, s), 8.46 (dd, 4H), 7.86 (t, 
2H, J 8 Hz), 7.48 (d, 1H, J 7.6 Hz), 7.18 (d, 1H, J 8 Hz), 7.0 (s, 1H,), 6.93 (t, 1H, J 8 Hz), 6.8 (t, 
1H, J 7.2 Hz), 5.89 (dd, 1H, J1 9.6 Hz, J2 5.2 Hz), 3.65 (dd, 1H, J1 15.2 Hz, J2 5.2 Hz), 5.56 (dd, 
1H, J1 14.8 Hz, J2 9.6 Hz),13C NMR (DMSO-d6, 500 MHz) δ ppm: 171.2, 163.3, 136.1, 134.9, 
131.5, 127.6, 127.4, 123.7, 121.6, 121.0, 118.5, 118.2, 111.5, 110.4, 53.9, and 24.2 ppm. 
        Preparation of (S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-propionic acid (44aS).  
Pyridine solution (600mL) of phthalic anhydride (2.0 g; 0.013 mol) and L- alanine (1 g; 0.011 
mol) was refluxed for 10 h.  Volume of the reaction mixture was reduced to ~ 5 mL and hot 
reaction mixture was added to mixture of ethyl acetate (250 ml) and aq. hydrochloric acid (250 
mL water and 50 mL concd. HCl).  Formed solid precipitate was separated by filtration, washed 
with water (3x20 mL) and recrystalized with water to afford 2.23 g (91%) pure white crystals. 
Mp 148.5-150 ºC. 1H NMR (DMSO-d6, 500 MHz): δ ppm: 7.85-7.90 (m, 4H) 4.87 (q, 1H, J 7 
Hz), 1.55 (3H, d, J2 7.5 Hz). 13C NMR (DMSO-d6, 500 MHz): δ ppm: 171.1, 167.2 (carbonyls), 
134.8, 131.3, 123.3 (3 aromatic carbons), 46.9(chiral carbon CH), and 14.8 ppm (methylene 
carbon). MS-ES- (CH3OH) m/z 218.2 (100% M-H+).  
            Preparation of (R)- 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-propionic acid (44aR).  
The R stereoisomer was prepared in 88% isolated yield by following the procedure described for 
the S stereoisomer.  The spectral characteristics for this compound are identical to the spectral 
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characteristics of the S stereoisomer. Mp 148.5-150 ºC. 1H NMR (DMSO-d6, 500 MHz): δ ppm: 
7.85-7.90 (m, 4H) 4.86 (q, 1H, J 7 Hz), 1.54 (3H, d, J2 7.5 Hz). 13C NMR (DMSO-d6, 500 MHz): 
δ ppm: 171.1, 167.2 (carbonyls), 134.8, 131.3, 123.3 (3 aromatic carbons), 47.0 (chiral carbon 
CH), and 14.8 ppm (methylene carbon).       
           Preparation of (S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-phenyl-propionic acid 
(44bS).  Pyridine solution (600 mL) of phthalic anhydride (2.0 g; 0.013 mol) and L-phenyl 
alanine (1.65 g; 0.01 mol) was refluxed for 12 h.  Volume of the reaction mixture was reduced to 
~ 5 mL and hot reaction mixture was added to ice cooled aq. hydrochloric acid (150 mL water 
and 50 mL concd. HCl).  Formed solid white precipitate was separated by filtration, washed with 
water (3x20 mL) and dried in oven at 60 °C for a few hours to afford 2.8 g (95%) pure product. 
Mp 186-188 °C. 1H NMR (500 MHz; DMSO-d6) 7.82 (s, 4H) 7.15 (m, 5H), 5.13 (dd, 1H, J1 11.5 
Hz; J2 4.5 Hz), 3.49 (dd, 1H, J1 15.5 Hz; J2 4.5 Hz), 3.35 (dd, 1H, J1 14 Hz; J2 11.5 Hz). 13C 
NMR (DMSO-d6, 500 MHz): δ ppm: 170.1, 167.1 (carbonyls), 137.3, 134.9, 130.7, 128.7, 128.3, 
126.6, 123.4 (7 aromatic carbons), 52.9 (chiral carbon CH), and 33.9 ppm (methylene carbon). 
MS-ES- (CH3OH) m/z 250.3 (15%, M-CO2-H+), 294.2 (100%, M-H+), 589.4 (25%, 2M-H+).   
           Preparation of (R)- 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-phenyl-propionic acid 
(44bR).  The R stereoisomer was prepared in 93% isolated yield by following the procedure 
described for the S stereoisomer.  The spectral characteristics for this compound are identical to 
the spectral characteristics of the S stereoisomer. Mp 186-188 °C. 1H NMR (500 MHz; DMSO-
d6) 7.80 (s, 4H) 7.14 (m, 5H), 5.14 (dd, 1H, J1 12 Hz; J2 5 Hz), 3.50 (dd, 1H, J1 14 Hz; J2 5 Hz), 
3.37 (dd, 1H, J1 14.5 Hz; J2 11.5 Hz). 13C NMR (DMSO-d6, 500 MHz): δ ppm: 170.3, 167.3 
(carbonyls), 137.4, 135.0, 130.8, 128.8, 128.4, 126.7, 123.5 (7 aromatic carbons), 53.1 (chiral 
carbon CH), and 34.1 ppm (methylene carbon). 
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        Preparation of (S)- 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic 
acid (44cS). Pyridine solution (600 mL) of phthalic anhydride (1.48 g; 0.01 mol) and L-
tryptophan (2.04 g; 0.01 mol) was refluxed for 12 h.  Volume of the reaction mixture was 
reduced to ~ 5 mL and hot reaction mixture was added to ice cooled aqueous hydrochloric acid 
(150 mL water and 50 concd. HCl).  Formed solid precipitate was separated by filtration, washed 
with water (3x20 mL) and dried in oven at 60 °C for a few hours to afford 2.8 g (84%) pure 
product. mp 180-182 ºC. 1H NMR (DMSO-d6, 500 MHz): δ ppm: 10.74 (s, 1H, pyrrol ring NH) 
7.79 (s, 4H, benzene ring), 7.48 (d, 1H, J  7.5 Hz), 7.26 (d, 1H, J 7.5 Hz) 7.03 (s, 1H, pyrrol 
ring), 7.00 (1H, t, J  8 Hz) 6.90 (t, 1H, J  7.5 Hz) 5.12 (dd, 1H, J1 9.5 Hz ; J2 6.5 Hz) 3.58 (ddd, 
2H). 13C NMR (DMSO-d6, 500 MHz): δ ppm: 170.5, 167.3 (carbonyls), 136.1, 134.9, 130.9, 
127.0, 123.5, 123.4, 121.1, 118.5, 118.0, 111.6, 109.8 (11 aromatic carbons), 52.7 (chiral carbon 
CH), and 24.2 ppm (methylene carbon). MS-ES-  (CH3OH) m/z 333.1 (100%, M-H+), 667.1 
(70%, 2M-H+).  Anal. Calcd for C19H14N2O4 (334.33) : C, 68.26; H, 4.22; N, 8.38. Found: C, 
68.31; H, 4.22; N, 8.35. 
         Preparation of (R)- 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-(1H-indol-3-yl)-
propionic acid (44cR).   The R stereoisomer was prepared in 79% isolated yield by following 
the procedure described for the S stereoisomer.  The spectral characteristics for this compound 
are identical to the spectral characteristics of the S stereoisomer. Mp 180-182 ºC. 1H NMR 
(DMSO-d6, 500 MHz): δ ppm: 10.72 (1H, s, pyrrol ring NH) 7.80 (4H, s, benzene ring), 7.47 (d, 
1H, J  7.5 Hz), 7.24 (d, 1H, J 8 Hz) 7.01 (s, 1H, pyrrol ring), 7.98 (t, 1H, J  7.5  Hz) 6.88 (t, 1H, 
J  7.5 Hz) 5.09 (dd, 1H, J1 10 Hz ; J2  6 Hz) 3.55 (ddd  2H,). 13C NMR (DMSO-d6, 500 MHz): δ 
ppm: 170.5, 167.4 (carbonyls), 136.1, 134.9, 130.9, 127.0, 123.5, 123.4, 121.1, 118.0, 111.6, 
109.8 (11 aromatic carbons), 52.8 (chiral carbon CH), and 24.2 (methylene carbon). 
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        Preparation of (RS)- 2-(1,3-Dioxo-octahydro-isoindol-2-yl)-propionic acid (45aRS).  
Pyridine solution (500 mL) of 1,2-cyclohexanedicarboxylic anhydride (3.2 g; 0.021 mol) and DL 
alanine (1.78 g; 0.02 mol) was refluxed for 10 h.  Volume of the reaction mixture was reduced to 
~ 5 mL and hot reaction mixture was added to mixture of ethyl acetate (250 mL) and aq. 
hydrochloric acid (250 mL water and 50mL concd. HCl).  The ethyl acetate layer was separated 
and washed with water (3x20 mL) and then removed under reduced pressure. The product was 
recrystalized from water and dried in air for a few hours to afford 4.05 g (90 %) pure product. 
Mp 148-149 °C. 1H NMR (DMSO-d6, 500 MHz): δ ppm:  4.62 (q, 1H, J  7.5 Hz), 2.94 (m, 2H), 
1.73-1.61(m, 4H), 1.38 (d, 3H, J 7.5 Hz), 1.29-1.26 (m, 4H). 13C NMR (DMSO-d6, 500 MHz): δ 
ppm: 178.9, 178.7, 170.9 (carbonyls), 46.9 (chiral carbon), 39.0, 23.1, 21.3, 21.3, 21.1, 14.1 
(aliphatic carbon). MS-ES- (CH3OH) m/z 224.1 (100% M-H+). 
           Preparation of (RS)- 2-(1,3-Dioxo-octahydro-isoindol-2-yl)-3-phenyl-propionic acid 
(45bRS).  Pyridine solution (500 mL) of 1,2-cyclohexanedicarboxylic anhydride (3.85 g; 0.025 
mol) and DL-phenyl alanine (3.3 g; 0.02 mol) was refluxed for 10 h. Volume of the reaction 
mixture was reduced to ~ 5 mL and hot reaction mixture was added to aqueous hydrochloric acid 
(300 mL water and 50 concd. HCl).  Formed oily residue was stirred for 1 hour and obtained 
precipitate was separated by filtration, washed with water (3x20 mL) and dried in air for a few 
hours. Recrystalization from water gives 5.5 g (92 %) pure product. Mp 145-147 °C. 1H NMR 
(DMSO-d6, 500 MHz): δ ppm: 7.23 (t, 2H, J 7.5 Hz), 7.17(t, 1H, J 7 Hz), 7.13(d, 2H, J 6.5 Hz), 
4.93 (dd, 1H, J1 12 Hz ; J2 5 Hz), 3.36 (dd, 1H, J1 14 Hz ; J2 5 Hz), 3.26 (dd, 1H, J1 13.5 Hz ; J2 
12 Hz).2.75 (m, 2H), 1.56-0.95 (m, 8H). 13C NMR (DMSO-d6, 500 MHz): δ ppm: 178.8, 178.6, 
169.9 (carbonyls), 137.1, 128.9, 128.2, 126.6 (4 aromatic carbons), 52.9 (chiral carbon), 52.2, 
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38.6, 38.5, 33.3, 23.4, 22.4, 21.2, 21.1 ppm (aliphatic carbon). MS-ES- (CH3OH) m/z 300.1 
(100%, M-H+) 601.2 (20%, 2M-H+). 
            Preparation of (S)- 2-(1,3-Dioxo-octahydro-isoindol-2-yl)-3-(1H-indol-3-yl)-
propionic acid (45cS).  Pyridine solution (600 mL) of 1,2-cyclohexanedicarboxylic anhydride 
(1.7 g; 0.011 mol) and L-tryptophan (2.04 g; 0.01 mol) was refluxed for 12 h.  Volume of the 
reaction mixture was reduced to ~ 5 mL and hot reaction mixture was added to ice cooled 
aqueous hydrochloric acid (150 mL water and 50mL concd. HCl).  Formed solid precipitate was 
separated by filtration, washed with water (3x20 mL) and dried in oven at 60°C for a few hours 
to afford 2.1 g (93%) pure product. Mp 200-201 °C. 1H NMR (DMSO-d6, 500 MHz): δ ppm: 
10.83 (s, 1H, pyrrol ring NH) 7.44 (d, 1H, J 8 Hz), 7.30 (d, 1H, J 8 Hz) 7.04(s, 1H, pyrrol ring)  
7.03 (t, 1H) 6.95 (t, 1H, J 7 Hz) 4.91 (dd, 2H, J1 11 Hz ; J2  5 Hz) 3.45 (ddd, 2H), 2.72 (q, 1H, J1 
7 Hz), 2.67 (q, 1H, J1 7 Hz), 1.50-0.95 (m, 8H). 13C NMR (DMSO-d6, 500 MHz): δ ppm: 178.9, 
178.6, 170.3 (carbonyls), 136.0, 127.1, 123.6, 120.9, 118.4, 118.1, 111.4, 109.5, (8 aromatic 
carbons), 52.3, 38.8, 38.6, 23.4, 23.3, 22.3, 21.2, 21.0 (8 aliphatic carbon). MS-ES- (CH3OH) 
m/z 339.1 (100% M-H+) 679.2 (100% 2M-H+). Anal. Calcd for C19H20N2O4 (340.37) : C, 67.05; 
H, 5.92; N, 8.23. Found: C, 66.91; H, 5.92; N, 8.23. 
          Preparation of (R)- 2-(1,3-Dioxo-octahydro-isoindol-2-yl)-3-(1H-indol-3-yl)-propionic 
acid (45cR).  The R stereoisomer was prepared in 92% isolated yield by following the procedure 
described for the S stereoisomer.  The spectral characteristics for this compound are identical to 
the spectral characteristics of the S stereoisomer. Mp 200-201 °C. 1H NMR (DMSO-d6, 500 
MHz): δ ppm: 10.82 (s, 1H, pyrrol ring NH) 7.44 (d, 1H, J 8 Hz), 7.30 (d, 1H, J 7.5 Hz), 7.04 (s, 
1H, pyrrol ring),  7.03 (t, 1H), 6.95 (t, 1H, J 7 Hz), 4.91 (dd, 2H, J1 11 Hz ; J2  5 Hz), 3.48 (dd, 
2H, J1 15 Hz ; J2  11 Hz), 3.40 (dd, 2H, J1 15.5 Hz ; J2  5 Hz), 2.73 (q, 1H, J1 7 Hz), 2.67 (q, 1H, 
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J1 7.5 Hz), 1.50-0.95 (m, 8H). 13C NMR (DMSO-d6, 500 MHz): δ ppm: 178.9, 178.5, 170.2 
(carbonyls), 136.0, 127.1, 123.6, 120.9, 118.4, 118.1, 111.3, 109.5, (8 aromatic carbons), 52.2, 
38.7, 38.6, 23.3, 23.4, 22.2, 21.2, 21.0 (8 aliphatic carbon). 
  Preparation of (S)-N-(1-carboxyethyl)succinamic acid (46aS).  Water solution (5 mL) 
of S-Alanine (1.5 g; 0.017 mol) was slowly added into stirring tetrahydrofuran solution (200 mL) 
of succinic anhydride (1g; 0.01 mol).  Resulting suspension was stirred at 30ºC for 1 h.  Solid 
was separated by filtration and filtrate was evaporated under reduced pressure.  Liquid residue 
was mixed with ethyl acetate and the resulting mixture was dried over anhydrous sodium sulfate.  
Drying reagent was removed by filtration and filtrate was evaporated to solid residue and solid 
residue was slurried in petroleum ether.  Product was isolated by filtration of white suspension in 
79% yield. Mp 152-155 ºC.  1H NMR (D2O, 500 MHz) δ ppm: 4.35 (q, 1H, chiral CH; J 7 Hz), 
2.69 (s, 4H, two CH2 groups of the succinic acid moiety) and 1.42 (d, 3H, J 7.5 Hz).  13C NMR 
(D2O, drop of DMSO-d6 added for reference, 500 MHz) δ ppm: 177.5, 177.4, 175.2 (carbonyl 
carbon), 49.4, 30.5, 29.8, 29.5 (four aliphatic carbon).  ES-MS- m/z 188.1 (85%, M-H+), 377.3 
(100%, 2M-H+), and 566.0 (30%, 3M-H+).  Anal. Calcd for C7H11NO5 (189.06): C, 44.45; H, 
5.86; N, 7.40 Found: C, 44.37; H, 5.98; N, 7.33. 
 Preparation of (R)-N-(1-carboxyethyl)succinamic acid (46aR). 
The R isomer was prepared by following the same synthetic procedure with 83% isolated yield.  
The spectroscopic characteristics are identical to the S isomer. . mp 1510-153 ºC.  1H NMR 
(D2O, 500 MHz) δ ppm: 4.34 (q, 1H, chiral CH; J 7 Hz), 2.68(s, 4H, two CH2 groups of the 
succinic acid moiety) and 1.41 (d, 3H, J 7 Hz).  13C NMR (D2O, drop of DMSO-d6 added for 
reference, 500 MHz) δ ppm: 177.7, 177.4, 175.1 (carbonyl carbon), 49.3, 30.4, 29.7, 29.4(four 
aliphatic carbon). 
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 Preparation of (S)-N-(1-carboxy-2-phenylethyl)succinamic acid (46bS).  
Tetrahydrofuran (500 mL) suspension of phenylalanine (1.65 g; 0.01 mol) and succinic 
anhydride (1.0 g; 0.01 mol) was refluxed until the suspension becomes clear solution 
(approximately 30 h).  Solvent was evaporated under reduced pressure.  Solid residue was 
sclurried in petroleum ether (100 mL), separated by filtration, and washed with petroleum ether 
(3x20 mL) and dried at 60 ºC for a few hours.  The isolated yield is 2.5 g (95%) of pure product. 
mp. 127-129 ºC.  1H NMR (DMSO-d6, 500 MHz) δ ppm:  8.15 (d, 1H, amide NH, J 8 Hz) 7.25 
(m, 5H benzene ring), 4.50 (ddd, 1H chiral), 3.05 (dd, 1H, J1 13.5 Hz; J2 5 Hz), 2.86 (dd, 1H, J1 
13.5 Hz; J2 9.5 Hz), and 2.35 (s, 4H aliphatic two CH2 group).  13C NMR (DMSO-d6, 500 MHz) 
δ ppm:  173.8, 173.1, 171.1 (carbonyls), 129.2, 128.2, 126.4 (aromatic carbons), 53.6, 37.0, 29.9, 
and 29.1 (four aliphatic carbon).  MS-ES+ m/z 266.1 (22%, M+H+) and 288.1 (100%, M+Na+).  
Anal. Calcd for C13H15NO5 (265.10): C, 58.86; H, 5.70; N, 5.28 Found: C, 58.92; H, 5.77; N, 
5.15. 
 Preparation of (R)-N-(1-carboxy-2-phenylethyl)succinamic acid (46bR).  The R 
stereoisomer was prepared in 93% isolated yield by following the procedure described for the S 
stereoisomer.  The spectral characteristics for this compound are identical to the spectral 
characteristics of the S stereoisomer. Mp. 127-129 ºC.  1H NMR (DMSO-d6, 500 MHz) δ ppm:  
8.14 (d, 1H, amide NH, J =8Hz) 7.21 (m, 5H benzene ring), 4.69 (ddd, 1H chiral), 3.14 (dd, 1H, 
J1 13 Hz; J2 5 Hz), 2.96 (dd, 1H, J1 13 Hz; J2 8 Hz), and 2.48 (s, 4H aliphatic two CH2 group).  
13C-NMR (DMSO-d6, 500 MHz) δ ppm:  174.5, 173.3, 172.7 (carbonyls), 130.5, 129.4, 127.7 
(aromatic carbons), 54.6, 38.4, 31.2, and 29.9 (four aliphatic carbon).   
 Preparation of (S)-N-[1-carboxy-2-(1H-indol-3-yl)ethyl]succinamic acid (46cS).   
Tetrahydrofuran (1 L) suspension of L-tryptophan (2 g; 0.01 mol) and succinic anhydride (1 g; 
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0.01 mol) was refluxed until it became solution (approximately 40 h).  Solvent was evaporated 
and solid residue was mixed with petroleum ether (200 mL).  Solid material was separated by 
filtration, washed with petroleum ether (3x 20 mL), and dried at 60 °C for several hours to afford 
2.8 g (92%) of pure product. Mp (hydroscopic).  1H NMR (DMSO-d6, 500 MHz) δ ppm: 10.82 
(s, 1H the pyrrole ring NH) 8.15 (d, 1H amide hydrogen, J  7.5 Hz), 7.52 (d, 1H benzene ring H, 
J  7.5 Hz), 7.32 (d, 1H, J 8 Hz), 7.14 (s, 1H the pyrrole ring CH)  7.05 (t, 1H, J  7 Hz) 6.97 (t, 
1H, J  7 Hz) 4.46 (ddd, 1H) 3.14 (dd, 1H, J1 14 Hz; J2 5.5 Hz) 3.00 (dd, 1H, J1 14 Hz ; J2 8 Hz), 
2.35 ppm (s, 4H aliphatic two CH2 group hydrogen).  13C NMR (DMSO-d6, 400 MHz) δ ppm: 
173.8, 173.5, 171.1 (carbonyls), 136.1, 127.3, 123.6, 121.0, 118.4, 118.2, 111.4, 109.9 (8 
aromatic carbons), 53.1, 29.9, 29.1, and 27.2 ppm (four aliphatic carbon). MS-ES- m/z 303.1 
(35%, M-H+), 431.3 (15%, 3M-CO2-2H+), and 607.1(100%, 2M-H+).  Anal. Calcd for 
C15H16N2O5 (304.30): C, 59.21; H, 5.30; N, 9.21 Found: C, 59.15; H, 5.38; N, 9.16. 
 Preparation of (R)-N-[1-carboxy-2-(1H-indol-3-yl)ethyl]succinamic acid (46cR). The R 
stereoisomer was prepared in 96% yield by following same procedure outlined for the S 
stereoisomer.  All spectra of R stereoisomer are identical to the S stereoisomer spectra. Mp. 
(hygroscopic).  1H NMR (DMSO-d6, 500 MHz) δ ppm: 10.83 (s, 1H the pyrrole ring NH) 8.16 
(d, 1H amide hydrogen, J  7.5 Hz), 7.54 (d, 1H benzene ring H, J  8 Hz), 7.34 (d, 1H, J 8 Hz), 
7.15 (s, 1H the pyrrole ring CH)  7.07 (t, 1H, J  7.5 Hz) 6.99 (t, 1H, J  7 Hz) 4.47 (ddd, 1H) 3.17 
(dd, 1H, J1 14.5 Hz; J2 5.5 Hz) 3.02 (dd, 1H, J1 14 Hz ; J2 8 Hz), 2.37 ppm (s, 4H aliphatic two 
CH2 group hydrogen).  13C NMR (DMSO-d6, 400 MHz) δ ppm: 173.9, 173.5, 171.1 (carbonyls), 
136.1, 127.3, 123.7, 121.0, 118.4, 118.3, 111.4, 109.9 (8 aromatic carbons), 53.1, 29.9, 29.1, and 
27.3 ppm (four aliphatic carbon). 
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         Preparation of (Benzhydrylidene-amino)-acetic acid ethyl ester (49): A solution of 
benzophenone imine 47 (1 g, 0.0052 mol) and glycine ethyl ester hydrochloride 48 (0.77 g, 
0.0052 mol) in 20 mL methylene chloride was stirred in 100 mL round bottom flask covered 
with CaCl2 tube at room temperature for 24 h. The reaction mixture was filtered to remove 
NH4Cl and the filtrate was evaporated to dryness on a rotary evaporator. The residue was stirred 
in 20 mL of ether, filtered, washed with 20 mL of water, and dried with anhydrous MgSO4. 
Filtered and removal of solvent gave 49 which can be recrystallized using ether/hexane. Weight 
of white crystals 1.31 g (94%). 1H NMR (CDCl3, 500 MHz): δ ppm: 7.0-7.6 (m, 10H), 4.13 (s, 
2H), 4.14 (q, 2H, J 7.5 Hz), 1.2 (t, 3H, J 7.5 Hz). 13C NMR (DMSO-d6, 500 MHz) δ ppm:172.1, 
170.9, 130.7, 129.0 128.9, 128.8, 128.3, 127.9, 61.1, 55.9, 14.4. 
         Preparation of acetoxy-(benzhydrylidene-amino)-acetic acid ethyl ester (50): A 
solution of N-bromosuccinamide ( 1.31 g; 0.005 mol) dissolved in 10 mL dry DMF was added 
dropwise at room temperature with stirring over three hours to a mixture of shiff base 49 (1.16 g, 
0.0065 mol), anhydrous sodium acetate (1.23 g; 0.015 mol) in  10 mL DMF. The mixture was 
stirred at room temperature overnight with exclusion of moisture (CaCl2 tube), poured into 100 
mL of water, extracted with ether (3x 15 mL), the ether extracts were washed with water, dried 
anhydrous MgSO4, filtered through a 3 cm pad of silica gel and the solvent was removed under 
reduced pressure. Resulting yellow liquid weight 1.14 g (70%). 1H NMR (CDCl3, 500 MHz): δ 
ppm: 7.2-7.7 (m, 10H), 6.18 (s, 1H), 4.22 (q, 2H, J 7 Hz), 2.18 (s, 3H), 1.28 (t, 3H, J 7 Hz). 
           Preparation of (S)- 2-[7-(1-Carboxy-ethyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-
benzo[lmn][3,8]phenanthrolin-2-yl]-propionic acid (53aS).  A pyridine solution (600 mL) of 
1,4,5,8-naphthalenetetracarboxylic dianhydride (1.34 g; 0.005 mol) and alanine (0.89 g; 0.01 
mol) was refluxed for 12 h.  The volume of the reaction mixture was reduced to ~10 mL and the 
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hot reaction mixture was added to aq. hydrochloric acid (300 mL water and 100 mL concd. HCl).  
The formed solid precipitate was separated by filtration, washed with water (3x20 mL) and oven 
dried at 100 ºC for a few hours to afford 1.86 g (91%) pure product. Mp. 343-345 °C. 1H NMR 
(DMSO-d6, 500 MHz): δ ppm: 8.69 (s, 4H naphthalene ring) 5.59 (q, 2H, J 6.5 Hz) 1.57 (d, 3H, 
J 7 Hz). 13C NMR (DMSO-d6, 500 MHz): δ ppm: 171.2 (two equivalent carbonyls of carboxylic 
acid) 162.1(four equivalent carbonyls), 131.1, 126.2 (aromatic carbons), 49.2 (chiral carbon), 
14.5(methylene carbon). MS-ES-  (CH3OH) m/z 364.9 (65%, M-CO2-H+), 410 (100%, M-H+), 
818 (95%, 2M-2H+) . Anal. Calcd for C20H14N2O8 (534.47) : C, 58.54; H, 3.44; N, 6.83. Found: 
C, 57.50; H, 3.49; N, 6.70. 
 Preparation of (R)- 2-[7-(1-Carboxy-ethyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-
benzo[lmn][3,8]phenanthrolin-2-yl]-propionic acid (53aR). The stereoisomer R was prepared 
in 90% yield by following the procedure for preparation of the S isomer.  The NMR and ESIMS 
spectra of R and S stereoisomers are identical. Mp 343-345 °C. 1H NMR (DMSO-d6, 500 MHz): 
δ 8.66 (s, 4H, naphthaline ring) 5.57 (q, 2H, J 7 Hz) 1.55 (d, 3H, J 6.5 Hz). 13C NMR (DMSO-
d6, 500 MHz): δ 171.3 (two equivalent carbonyl of carboxylic acid) 162.1(four equivalent 
carbonyls), 131.1, 126.3 (aromatic carbons), 49.2 (chiral carbon), 14.5(methylene carbon). 
 Preparation of (RS)- 2-[7-(1-Carboxy-2-phenyl-ethyl)-1,3,6,8-tetraoxo-3,6,7,8-
tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-3-phenyl-propionic acid (53bRS). A 
pyridine solution (500 mL) of 1,4,5,8-naphthalenetetracarboxylic dianhydride (1.34 g; 0.005 
mol) and DL phenyl alanine (1.65 g; 0.01 mol) was refluxed for 12 h. The volume of the reaction 
mixture was reduced to ~ 10 mL and the hot reaction mixture was added to aq. hydrochloric acid 
(300 mL water and 100 concd. HCl).  The formed yellow solid precipitate was separated by 
filtration, washed with water (3x20 mL) and oven dried for a few hours to afford 2.81 g (96 %) 
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pure product. M.p. 352-354 °C. 1H NMR (DMSO-d6, 500 MHz): δ ppm: 8.64 (s, 4H naphthalene 
ring), 7.16 (d, 4H phenyl ring, J 7 Hz) 7.11(t, 4H, phenyl ring J 7.5 Hz) 7.04 (t, 2H phenyl ring, J 
7 Hz) 5.86 (dd, 2H, J1 5.5 Hz ; J2  9.5Hz) 3.59 (dd, 2H, J1 14 Hz ; J2 5.5 Hz) 3.32 (dd, 2H,  J1 14 
Hz ; J2 9.5 Hz). 13C NMR (DMSO-d6, 400 MHz): δ ppm: 170.3 (two equivalent carbonyls of 
carboxylic acid) 162.0(four equivalent carbonyls), 137.8, 131.3, 128.9, 128.2, 126.4, 126.0, 
125.7(aromatic carbons), 54.6(chiral carbon), 34.3(methylene carbon). MS-ES-  (CH3OH) m/z 
517.2 (85%, M-CO2-H+), 562 (100%, M-H+). Anal. Calcd for  C32H22N2O8 (562.53) : C, 68.32; 
H, 3.94; N, 4.98. Found : C, 67.70; H, 3.89; N, 4.94. 
 Preparation of (S)- 2-{7-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-1,3,6,8-tetraoxo-3,6,7,8-
tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl}-3-(1H-indol-3-yl)-propionic acid (53cS). 
A pyridine solution (600mL) of 1,4,5,8-naphthalenetetracarboxylic dianhydride (1.34 g; 0.005 
mol) and L-tryptophan (2.04 g; 0.01 mol) was refluxed for 12 h. The volume of the reaction 
mixture was reduced to ~ 10 mL and the hot reaction mixture was added to aq. hydrochloric acid 
(300 mL water and 100 concd. HCl).  The formed black solid precipitate was separated by 
filtration, washed with water (3x20 mL) and oven dried for a few hours to afford 3.1 g (97%) 
pure product. M.p. 286-288 ºC. 1H NMR (DMSO-d6, 500 MHz): δ ppm: 10.65 (s, 2H pyrrol ring 
NH) 8.60 (s, 4H naphthalene ring), 7.47 (d, 2H, J 8 Hz), 7.19 (d, 2H, J 8.5 Hz) 7.05 (2H, s, 
pyrrol ring) 6.93 (t, 2H, J 7.5 Hz) 6.80 (t, 2H, J 7.5 Hz) 5.86 (dd, 2H, J1 9.5 Hz ; J2 5.5 Hz) 3.69 
(dd, 2H, J1 14.5 Hz ; J2 5.5 Hz) 3.49 (dd, 2H, J1 15 Hz ; J2 9 Hz). 13C NMR (DMSO-d6, 400 
MHz): δ ppm: 170.7 (two equivalent carbonyl of carboxylic acid) 162.1(four equivalent 
carbonyls), 135.9, 131.2, 127.1, 125.9, 125.7, 123.8, 120.9, 118.3, 118.0, 111.4 and 110.2 (11 
aromatic carbons), 54.3(chiral carbon), 24.2(methylene carbon). MS-ES-  (CH3OH) m/z 595.8 
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(65%, M-CO2-H+), 640.7 (100%, M-H+),.  Anal. Calcd for C36H24N4O8 (640.6): C, 65.70; H, 
3.78; N, 8.75. Found: C, 65.06; H, 4.08; N, 8.38. 
 Preparation of (R)- 2-{7-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-1,3,6,8-tetraoxo-3,6,7,8-
tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl}-3-(1H-indol-3-yl)-propionic acid 
(53cR).  The stereoisomer R was prepared in 94% yield by following the procedure for the 
preparation of the S isomer.  The NMR and MS-ES spectra of R and S stereoisomers are 
identical. M.p. 286-288 ºC. 1H NMR (DMSO-d6, 500 MHz): δ ppm: 10.64 (s, 2H pyrrol ring 
NH) 8.59 (s, 4H naphthalene ring), 7.46 (d, 2H, J 8 Hz), 7.19 (d, 2H, J 8.5 Hz) 7.04 (2H, s, 
pyrrol ring) 6.92 (t, 2H, J 7 Hz) 6.79 (t, 2H, J 7 Hz) 5.85 (dd, 2H, J1 9 Hz ; J2 5.5 Hz) 3.68 (dd, 
2H, J1 14.5 Hz ; J2 5.5 Hz) 3.49 (dd, 2H, J1 15 Hz ; J2 9 Hz). 13C NMR (DMSO-d6, 400 MHz): δ 
ppm: 170.7 (two equivalent carbonyl of carboxylic acid) 162.1(four equivalent carbonyls), 135.9, 
131.2, 127.1, 125.9, 125.7, 123.8, 120.9, 118.3, 118.0, 111.4 and 110.2 (11 aromatic carbons), 
54.3(chiral carbon), 24.1(methylene carbon). 
        Preparation of (RS)- 2-[6-(1-Carboxy-ethyl)-1,3,5,7-tetraoxo-3,5,6,7-tetrahydro-1H-
pyrrolo[3,4-f]isoindol-2-yl]-propionic acid (54aRS).  Pyridine solution (600 mL) of 1,2,4,5-
benzenetetracarboxylic dianhydride (1.42 g; 0.0065 mol) and DL- alanine (1 g; 0.011 mol) was 
refluxed for 11 h.  Volume of the reaction mixture was reduced to ~ 5 mL and hot reaction 
mixture was added to ice cooled aqueous hydrochloric acid (150 mL water and 50mL concd. 
HCl).  Formed solid precipitate was separated by filtration, washed with water (3x20 mL) and 
dried in oven for a few hours to afford 1.6 g (81%) pure product. M.p. 297-298 ºC. 1H NMR 
(DMSO-d6, 500 MHz): δ ppm: 8.28 (s, 2H) 4.94 (q, 2H), 1.57 (d, 6H; J 7 Hz). 13C NMR 
(DMSO-d6, 500 MHz): δ ppm: 170.7, 165.5 (carbonyls), 136.8, 118.0 (2 aromatic carbons), 47.6 
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(chiral carbon CH), and 14.7 ppm (methyl carbon). MS-ES- (CH3OH) m/z 315.1 (65%, M-CO2-
H+), 359 (100%, M-H+), 718.8 (100% 2M-H+ ). 
         Preparation of (RS)- 2-{6-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-1,3,5,7-tetraoxo-
3,5,6,7-tetrahydro-1H-pyrrolo[3,4-f]isoindol-2-yl}-3-(1H-indol-3-yl)-propionic acid 
(54bRS).  Pyridine solution (600 mL) of 1,2,4,5-benzenetetracarboxylic dianhydride (1.09 g; 
0.005 mol) and DL-phenyl alanine (1.65 g; 0.01 mol) was refluxed approximately for 12 
h.Volume of the reaction mixture was reduced to ~ 5 mL and hot reaction mixture was added to 
ice cooled aqueous hydrochloric acid (150 mL water and 50 mL concd. HCl).  Formed solid 
white precipitate was separated by filtration, washed with water (3x20 mL) and dried in oven for 
a few hours to afford 2.3 g (90%) pure product. Mp 296-297.5 ºC. 1H NMR (DMSO-d6, 500 
MHz): δ ppm: 8.21 (s, 2H) 7.10-7.15 (m, 10 H), 5.16 (dd, 2H, J1 11 Hz ; J2 5 Hz), 3.50(dd, 2H, 
J1 14 Hz ; J2 5 Hz), 3.30 (dd, 2H,  J1 14 Hz ; J2 11.5 Hz). 13C NMR (DMSO-d6, 500 MHz): δ 
ppm: 169.6, 165.2 (carbonyls), 137.1, 136.2, 128.7, 128.4, 126.7 (6 aromatic carbons), 53.6 
(chiral carbon CH), and 33.9 ppm (methylene carbon). MS-ES- (CH3OH) m/z 467.3 (100%, M-
CO2-H+), 511.3 (50%, M-H+).  
          Preparation of (S)- 2-{6-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-1,3,5,7-tetraoxo-3,5,6,7-
tetrahydro-1H-pyrrolo[3,4-f]isoindol-2-yl}-3-(1H-indol-3-yl)-propionic acid (54cS). Pyridine 
solution (600 mL) of 1,2,4,5-benzenetetracarboxylic dianhydride (1.09 g; 0.005 mol) and L-
tryptophan (2.04 g; 0.01 mol) was refluxed overnight.  Volume of the reaction mixture was 
reduced to ~ 5 mL and hot reaction mixture was added to ice cooled aqueous hydrochloric acid 
(150 mL water and 50 mL concd. HCl).  Formed solid yellow precipitate was separated by 
filtration, washed with water (3x20 mL) and dried at 60 °C for few hours to afford 2.5 g (85%) 
pure product. Melting point range 192-194 °C. 1H NMR (DMSO-d6, 500 MHz): δ ppm: 10.71 (s, 
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2H, pyrrol ring NH) 8.13 (s, 2H, benzene ring), 7.47 (d, 2H, J 8 Hz,), 7.24 (d, 2H, J 8 Hz)  
7.03(s, 2H, pyrrol ring)  6.99 (t, 2H, J 7 Hz) 6.88 (t, 2H, J 7.5 Hz) 5.15 (dd, 2H, J1 11.5 Hz ; J2 
5Hz) 3.58 (dd, 2H, J1 14.5 Hz ; J2  5 Hz) 3.52 (dd, 2H, J1 14.5 Hz ; J2 11 Hz). 13C NMR 
(DMSO-d6, 400 MHz): δ ppm: 169.9 (two carbonyl of carboxylic acid) 165.4(four equivalent 
carbonyls), 136.3, 136.1, 126.9, 123.7, 121.1, 118.5, 118.3, 117.9, 111.5 and 109.5 (10 aromatic 
carbons), 52.3(chiral carbon CH), 24.2(methylene carbon). MS-ES-  (CH3OH) m/z 545.3 (35%, 
M-CO2-H+), 589.4 (100%, M-H+),.  Anal. Calcd for C32H22N4O8 (590.54): C, 65.08; H, 3.75; N, 
9.49. Found: C, 63.58; H, 3.91; N, 9.26. 
            Preparation of (R)- 2-{6-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-1,3,5,7-tetraoxo-
3,5,6,7-tetrahydro-1H-pyrrolo[3,4-f]isoindol-2-yl}-3-(1H-indol-3-yl)-propionic acid (54cR). 
The R stereoisomer was prepared in 89% isolated yield by following the procedure described for 
the S stereoisomer.  The spectral characteristics for this compound are identical to the spectral 
characteristics of the S stereoisomer. 1H NMR (DMSO-d6, 500 MHz): δ ppm: 10.73 (s, 2H, 
pyrrol ring NH) 8.15 (s, 2H, benzene ring), 7.47 (d, 2H, J 8 Hz,), 7.24 (d, 2H, J 8.5 Hz)  7.03(s, 
2H, pyrrol ring)  6.99 (t, 2H, J 7.5 Hz) 6.88 (t, 2H, J 7.5 Hz) 5.13 (dd, 2H, J1 10.5 Hz ; J2 5 Hz) 
3.57 (dd, 2H, J1 15 Hz ; J2 5 Hz) 3.51 (dd, 2H, J1 14.5 Hz ; J2 11 Hz). 13C NMR (DMSO-d6, 400 
MHz): δ ppm: 169.8 (two carbonyl of carboxylic acid) 165.3 (four equivalent carbonyls), 136.3, 
136.0, 126.8, 123.6, 121.0, 118.4, 118.3, 117.8, 111.4 and 109.4 (10 aromatic carbons), 53.2 
(chiral carbon CH), 24.1 (methylene carbon). 
           Preparation of 3-methyl-2-cyclopenten-1-one (57). Acetonyl acetone (0.4 mol, 45.6 g) 
and toluene (52 mL) were placed in a 250 mL 3 necked round bottom flask equipped with a 
thermometer and a magnetic stirring bar. A mixture of NaOH (4.0 g, 0.1 mol) and water (40 mL) 
was added at 22 ºC into the above flask. This two-layer mixture was then stirred and heated at 
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80-85 ºC for a period of six hours. The color of the two-phased mixture was dark brown and 
some tar formation was observed. The toluene layer was separated and washed once with 20 mL 
of saturated NaCl solution. The toluene was stripped of at 30-40º C (20 mm Hg) at reduced 
pressure and the 57 was collected by distillation at 45-70 ºC (5-15 mm Hg) to afford  17.7 g 
(46%) pure pale yellow product; bp 72-74 ºC/15 mm Hg. 1H NMR (CDCl3, 400 MHz): δ 5.83 (s, 
1H, =CH), 2.3-2.5 (m, 4H, 2CH2), 2.05 (s, 3H). 13C NMR (CDCl3, 400 MHz): δ 210.3 
(carbonyl), 179.1, 130.6, 35.7, 33.0, 19.4. 
            Preparation of 2,3-epoxy-3-methylcyclopentanone (57a). Into a reaction vessel with a 
reflux condenser were successively placed the catalyst HT(MO) (0.15 g), 3-methyl-2-
cyclopenten-1-one 3 ( 1.93 g, 20 mmol) and 30% aqueous hydrogen peroxide (3.4 mL, 30 
mmol). After the resultant heterogeneous mixture was stirred at 40 ºC for 3 h, the hydrotalcite 
was separated by filtration. The filtrate was treated with aqueous Na2SO3 followed by extraction 
with ethyl acetate. Removal of the solvent under reduced pressure afforded 2.04 g (91%) of pure 
57a; bp 65-67 ºC/ 15 torr. 1H NMR (CDCl3, 400 MHz): δ 3.16 (s, 1H), 1.9-2.4 (m, 4H, 2CH2 ), 
1.6 (s, 3H, CH3). 13C NMR (CDCl3, 400 MHz): δ 210.2 (carbonyl), 65.4, 60.7, 32.4, 27.2, 17.4. 
            Preparation of 3-methyl-3-tosylcyclopentanone (57b). To a stirred solution of 3-
methyl-2-cyclopentenone 57 (12 g, 0.125 mol) and sodium 4-methylbenzenesulfinate (27.8 g, 
0.156 mol) in water (100 mL), 1N HCl (200 mL) is added slowly in a thin stream. Stirring is 
continued for 18 h and the solid product then isolated by suction, washed with water and air 
dried; yield: 28.4 g (90%); mp 86-88 ºC. 1H NMR (CDCl3, 300 MHz): δ 7.78 (d, 2H, AA’ Tos-
H, J  8.1 Hz), 7.40 (d, 2H, BB’ Tos-H, J  8.4 Hz), 1.8-3.1 (m, 6H, 3CH2), 2.48 (s, 3H, Tos-CH3), 
1.42 (s, 3H, CH3). 13C NMR (CDCl3, 300 MHz): δ 213.6 (carbonyl), 145.5, 132.1, 130.2, 129.9, 
65.7, 46.4, 36.7, 29.9, 22.2, 21.8. 
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         Preparation of 3-methyl-3-tosylcyclopentanone 1,2-ethanediyl acetal (57c). A stirred 
mixture of 3-methyl-3-tosylcyclopentanone 57b (10 g, 0.04 mol), 2,2-dimethyl-1,3-dioxolane 
(13 mL, 0.12 mol), a trace amount of p-toluenesulfonic  acid, and benzene (80 mL) was heated at 
65-70 ºC and the liberated acetone distillate slowly through a small Claisen-Vigreux column at 
atmospheric pressure for a period of 2 hour. The progress of reaction was followed by NMR. 
After 2 hour saturated sodium hydrogen carbonate solution (50 mL) is added and heating is 
continued for 15 min. the mixture is then cooled and layers are separated. The organic layer is 
washed with water (3x50 mL) and dried with potassium carbonate. The solvent is removed under 
reduced pressure and crystallize from ice-cold diisopropyl ether to afford 57c in6.5 g (55%) 
yield; mp 86-88 ºC. 1H NMR (CDCl3, 400 MHz): δ 7.73 (d, 2H, AA’ Tos-H, J 7.6 Hz), 7.30 (d, 
2H, BB’ Tos-H, J 7.6 Hz), 3.8-3.9 (m, 4H, O-CH2-O-CH2), 1.4-2.7 (m, 6H, 3CH2), 2.41 (s, 3H, 
Tos-CH3), 1.39 (s, 3H, CH3). 13C NMR (CDCl3, 400 MHz): δ 144.8, 133.0, 130.2, 129.7, 116.5, 
66.7, 64.7, 64.4, 43.4, 35.6, 31.7, 23.4, 21.7. 
        Preparation of 3-methyl-2-cyclopentenone 1,2-ethanediyl acetal (57d). To a stirred 
solution of 3-methyl-3-tosylcyclopentanone 1,2-ethanediyl acetal 57c (3 g, 0.01 mol) in dry THF 
(10 mL) added very slowly 1.6 M solution of n-Butyl lithium (13.7 mL, 0.022 mol) in hexane at 
0 ºC. After 30 min, ether (10 mL) and water (2 mL) are added. The organic layer is separated, 
washed with water (3x5 mL), dried with anhydrous sodium sulfate, and evaporated to afford 
product 57d in 1.2 g(86%) yield; bp 47-48 ºC/4.5 torr. 1H NMR (CCl4, 400 MHz): δ 5.26 (s, 1H, 
=CH), 3.77 (s, 4H, O-CH2-O-CH2), 2.0-2.3 (m, 4H, 2CH2), 1.75 (s, 3H, CH3). 13C NMR (CCl4, 
400 MHz): δ 145.8, 125.8, 120.4, 64.2, 35.6, 33.6, 17.0.  
        Preparation of 2-Bromo-3-hydroxy-3-methyl-cyclopentanone 1,2-ethanediyl acetal 
(57e). Under an atmosphere of nitrogen, the olefin 57d (3 g, 0.022 mol) in DMSO (60 mL) was 
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treated with water (0.8 mL) and cooled to 10 ºC. With stirring, NBS (7.6 g, 0.043 mol) was 
added as one portion. After a short induction period of 2-3 min a yellow color developed and the 
solution became quite warm. The color of the solution deepened as the reaction progressed. 
Stirring for an additional 10-15 min was followed by quenching the reaction mixture in dilute 
NaHCO3 solution with concomitant discharge of color and extraction of the product into ether to 
afford 57e in 4.2 g (80%) yield. 1H NMR (CDCl3, 400 MHz): δ 4.27 (s, 1H), 3.8-4.1 (m, 4H, O-
CH2-O-CH2), 1.9-2.2 (m, 4H, 2CH2), 1.45 (s, 3H, CH3). 13C NMR (CDCl3, 400 MHz): δ 113.5, 
77.7, 66.6, 65.6, 64.8, 35.2, 33.4, 25.1. 
        Preparation of 2,3-epoxy-3-methylcyclopentanone 1,2-ethanediyl acetal (58).  To a 
stirred solution of the bromohydrin adduct 57e (4 g, 0.017 mol) in dry THF (10mL) added NaH 
under an atmosphere of nitrogen. The resulting mixture was stirred for 1 h followed by filtration 
and evaporation of solvent under reduced pressure afford α−β epoxy ketal 58 in 2.4 g (90%) 
yield. 1H NMR (CDCl3, 400 MHz): δ 3.9-4.1 (m, 4H, O-CH2-O-CH2), 3.06 (s, 1H), 1.6-2.0 (m, 
4H, 2CH2), 1.45 (s, 3H, CH3). 13C NMR (CDCl3, 400 MHz): δ 115.1, 65.3, 64.9, 61.9, 31.2, 
29.5, 17.9. 
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5.3 Optical Rotations of Guest Compounds 43 and 46 
 
                 Table 5.1 Optical rotations of guest compounds 43a, 43b and 43c 
 
Guest Compd. Optical Rotation 
 L-enantiomer D-enantiomer 
43a -19.5 (c 0.1, MeOH) +18.0 (c 0.1, MeOH) 
43b -31.6 (c 1, MeOH)   +28.4 (c 1, MeOH) 
43c -17.0 (c 0.1, H2O)   +16.2 (c 0.1, H2O) 
  
 
Table 5.2 Optical rotations of guest compounds 46a, 46b and 46c 
 
Guest Compd. Optical Rotation 
 L-enantiomer D-enantiomer 
46a +22.0 (c 1, MeOH) -21.6 (c 1, MeOH) 
46b -14.9 (c 1, MeOH) +13.4 (c 1, MeOH) 
46c +37.1 (c 1, MeOH) -32.8 (c 1, MeOH) 
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5.4 ESIMS of Guest Compounds with CDs 
 
 
 
Figure 5.1 Positive ESIMS of 43aS in methanol-water 
 
 
Figure 5.2 Negative ESIMS of 45bRS (0.001 M) in aqueous NaHCO3 (0.003 M) and β- CD 
(0.01 M) 
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Figure 5.3 Negative ESIMS of 45cS (0.001 M) in aqueous NaHCO3 (0.003 M) and γ-
cyclodextrin (γ−CD, 0.01 M) 
 
 
 
 
 
Figure 5.4 Negative ESIMS of 46aS in methanol-water 
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Figure 5.5 Negative ESIMS of 46bS (0.001 M) in aqueous NaHCO3 (3x10-3 M) and α-
cyclodextrin (γ−CD, 10-2 M) 
 
 
 
 
 
Figure 5.6 Negative ESIMS of 46bS (0.001 M) in aqueous NaHCO3 (3x10-3 M) and β-
cyclodextrin (γ−CD, 10-2 M) 
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Figure 5.7 Negative ESIMS of 46bS (0.001 M) in aqueous NaHCO3 (3x10-3 M) and γ-
cyclodextrin (γ−CD, 10-2 M) 
 
 
 
 
 
Figure 5.8 Negative ESIMS of 46cS (0.001 M) in aqueous NaHCO3 (3x10-3 M) and γ-
cyclodextrin (γ−CD, 10-2 M) 
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Figure 5.9 Negative ESIMS of 53aS (0.001 M) in aqueous NaHCO3 (3x10-3 M) and β-
cyclodextrin (γ−CD, 10-2 M) 
 
 
 
 
 
 
Figure 5.10 Negative ESIMS of 53aS (0.001 M) in aqueous NaHCO3 (3x10-3 M) and γ-
cyclodextrin (γ−CD, 10-2 M) 
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Figure 5.11 Negative ESIMS of 53bS (0.001 M) in aqueous NaHCO3 (3x10-3 M) and β-
cyclodextrin (γ−CD, 10-2 M) 
 
 
 
 
 
 
Figure 5.12 Negative ESIMS of 53bS (0.001 M) in aqueous NaHCO3 (3x10-3 M) and γ-
cyclodextrin (γ−CD, 10-2 M) 
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Figure 5.13 Negative ESIMS of 54aS (0.001 M) in aqueous NaHCO3 (3x10-3 M) and γ-
cyclodextrin (γ−CD, 10-2 M) 
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5.5 Binding Isotherms of Guest Compounds with CDs 
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Figure 5.14 Binding isotherm for the complexation of 43cS and γ-CD at 40 °C 
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Figure 5.15 Binding isotherm for the complexation of 43cS and γ-CD at 70 °C 
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Figure 5.16 Binding isotherm for the complexation of 43cR and γ-CD at 25 °C 
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Figure 5.17 Binding isotherm for the complexation of 44aS and β-CD at 25 °C 
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Figure 5.18 Binding isotherm for the complexation of 44cS and γ-CD at 25 °C 
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Figure 5.19 Binding isotherm for the complexation of 44cR and γ-CD at 25 °C 
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Figure 5.20 Binding isotherm for the complexation of 46cS and γ-CD at 25 °C 
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Figure 5.21 Binding isotherm for the complexation of 46cR and γ-CD at 25 °C 
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